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IMPORTANCE Radiofrequency denervation is a commonly used treatment for chronic low
back pain, but high-quality evidence for its effectiveness is lacking.
OBJECTIVE To evaluate the effectiveness of radiofrequency denervation added
to a standardized exercise program for patients with chronic low back pain.
DESIGN, SETTING, AND PARTICIPANTS Three pragmaticmulticenter, nonblinded randomized
clinical trials on the effectiveness of minimal interventional treatments for participants with
chronic low back pain (Mint study) were conducted in 16multidisciplinary pain clinics in the
Netherlands. Eligible participants were included between January 1, 2013, and October 24,
2014, and had chronic low back pain, a positive diagnostic block at the facet joints
(facet joint trial, 251 participants), sacroiliac joints (sacroiliac joint trial, 228 participants),
or a combination of facet joints, sacroiliac joints, or intervertebral disks (combination trial,
202 participants) and were unresponsive to conservative care.
INTERVENTIONS All participants received a 3-month standardized exercise program and
psychological support if needed. Participants in the intervention group received
radiofrequency denervation as well. This is usually a 1-time procedure, but themaximum
number of treatments in the trial was 3.
MAIN OUTCOMES ANDMEASURES The primary outcomewas pain intensity (numeric rating
scale, 0-10; whereby 0 indicated no pain and 10 indicated worst pain imaginable) measured
3months after the intervention. The prespecified minimal clinically important difference was
defined as 2 points or more. Final follow-up was at 12 months, ending October 2015.
RESULTS Among 681 participants who were randomized (mean age, 52.2 years; 421 women
[61.8%], mean baseline pain intensity, 7.1), 599 (88%) completed the 3-month follow-up, and
521 (77%) completed the 12-month follow-up. Themean difference in pain intensity between
the radiofrequency denervation and control groups at 3 months was −0.18 (95% CI, −0.76
to 0.40) in the facet joint trial; −0.71 (95% CI, −1.35 to −0.06) in the sacroiliac joint trial;
and −0.99 (95% CI, −1.73 to −0.25) in the combination trial.
CONCLUSIONS AND RELEVANCE In 3 randomized clinical trials of participants with chronic low
back pain originating in the facet joints, sacroiliac joints, or a combination of facet joints,
sacroiliac joints, or intervertebral disks, radiofrequency denervation combined with a
standardized exercise program resulted in either no improvement or no clinically important
improvement in chronic low back pain compared with a standardized exercise program alone.
The findings do not support the use of radiofrequency denervation to treat chronic low back
pain from these sources.
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L
ow back pain causes more disability than any other
condition and has major social and economic con-
sequences.1-3 In the Netherlands (16.5 million resi-
dents) the cost of low back pain was estimated at €3.5 billion
(US $3.9 billion) in 2007, and the majority of the costs were
attributable to patients with chronic low back pain. In the
United States (326 million residents), the costs of low back
pain have not been recently estimated; however, a study by
Dieleman et al4 evaluated health care spending from 1996 to
2013 in theUnitedStates andestimated thehealth care spend-
ing on low back and neck pain at $87.6 billion.
Potential sources of low back pain of the spinal column
include the facet joints, sacroiliac joints, and intervertebral
disks. These sources of pain were classified as mechanical
low back pain.5,6 Radiofrequency denervation is a commonly
used treatment in pain clinics for chronic low back pain.
In the United States, facet joint or sacroiliac joint interven-
tions in Medicare recipients increased from approximately
425000 interventions in 2000 to 2.2 million interventions in
2013.7 Radiofrequency denervation aims to prevent the con-
duction of nociceptive impulses through the use of an elec-
tric current that damages the pain-conducting nerve. The
effectiveness of radiofrequency denervation has not been
consistently demonstrated. However, there is consensus
among anesthesiologists that minimal interventional proce-
dures such as radiofrequency denervation are effective for
patients with mechanical low back pain.5 Systematic reviews
and multidisciplinary clinical guidelines concluded that
there is evidence of very low to moderate quality supporting
the effectiveness of radiofrequency denervation in clinical
practice for patients with chronic low back pain.5,8-10
The aim of this study was to evaluate whether radiofre-
quency denervation in addition to a standardized exercise
program ismore effective than the standardized exercise pro-
gramalone forpatientswithchronicmechanical lowbackpain.
Methods
Study Design and Participants
The Cost-Effectiveness of Minimal Interventional Proce-
dures for Patients with Chronic Low Back Pain (Mint)
study11 was an initiative to evaluate minimally invasive
treatments for patients with spinal column–related chronic
low back pain, consisting of 4 trials and an observational
study (participants who did not want to be randomized or
who did not meet the inclusion criteria for the trials were
asked to participate in the observational study, where they
received usual care). The full protocol is available in
Supplement 1. One trial was designed to evaluate radiofre-
quency denervation for pain from the intervertebral disks.
This trial was prematurely terminated because of a lack of
eligible participants. The other 3 trials are presented in this
article: (1) the facet joint trial, (2) the sacroiliac joint trial,
and (3) the combination trial (facet joint, sacroiliac joint, or
the intervertebral disk). The Medical Ethics Committee of
the Erasmus University Medical Centre in Rotterdam
granted ethical approval. Local research governance was
obtained from all participating pain clinics. All participants
gave written informed consent.
In 16 multidisciplinary pain clinics in the Netherlands,
pain specialists consecutively screened participants with
chronic low back pain. Inclusion criteria were pain consid-
ered to be related to the facet joint, sacroiliac joint, or a com-
bination of the facet joint, sacroiliac joint, or intervertebral
disk; aged 18 to 70 years; and no improvement in symptoms
after conservative treatment. Medical history and clinical
examination followed a standard format and were performed
by experienced clinicians to determine the likely source of
the pain. To be considered for a diagnostic sacroiliac joint
block, at least 3 of 6 provocation tests (compression test; dis-
traction test; Flexion, Abduction, and External Rotation
[FABER] test; Gaenslen test; thigh thrust test; Gillett test) had
to have positive results.12,13 Participants with suspected iso-
lated facet joint pain or isolated sacroiliac joint pain received
a diagnostic anesthetic block prior to randomization and
were only randomized if the diagnostic block was positive.
Participants with a suspected combination of sources of pain
were randomized based on participant history and physical
examination prior to receiving the diagnostic blocks.
This choice was made for ethical reasons. It would be unethi-
cal to give participants in the study multiple diagnostic
blocks (ie, a facet joint diagnostic block, a sacroiliac joint
diagnostic block, and a provocative discography) before
treatment. Furthermore, it is common practice in Dutch pain
clinics for participants with chronic low back pain due to
facet joints, sacroiliac joints, or intervertebral disks (based on
history taking and physical examination) to start with 1 diag-
nostic block. If the diagnostic block was positive, the inter-
vention was provided. If the diagnostic block was negative,
then another block was provided. If the second diagnostic
block was positive, the intervention was provided. If the sec-
ond diagnostic block was negative, the clinician provided a
third block. All participants were considered candidates for
intervention based on history taking and physical examina-
tion. For this reason, participants were randomized and
included in the combination trial after history taking and
physical examination, if the pain physician suspected that
the pain originated frommore than 1 source.
Key Points
Question What is the effectiveness of radiofrequency
denervation added to a standardized exercise program for patients
with chronic low back pain?
Findings In 3 randomized clinical trials including 681 participants
with chronic low back pain originating from the facet joints,
sacroiliac joints, or a combination of these or the intervertebral
disks, radiofrequency denervation combinedwith exercise
comparedwith exercise alone resulted in either no significant
difference in pain intensity, or a difference smaller than the
prespecifiedminimal clinically important difference after 3months.
Meaning The study findings do not support the use of
radiofrequency denervation for chronic low back pain originating
from these sources.
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Exclusion criteria for all trialswerepregnancy, severepsy-
chological problems (determined with psychological ques-
tionnaires), involvement in work-related conflicts or claims;
body mass index (BMI; calculated as weight in kilograms di-
vided by height in meters squared) higher than 35; or antico-
agulant drug therapy or coagulopathy.
Diagnostic Blocks
For the facet joints,14a22-gaugeneedlewas inserted to thepos-
terior primary root of the spinal nerve (medial branch) under
C-arm fluoroscopy. L3-4, L4-5, and L5-6 were selected for di-
agnostic blocks. The lateral imagewas checked to confirm the
correct position of the needle, after which 0.5mL of 2% lido-
caine was injected.
For the sacroiliac joints,14 a 25-gauge needle was inserted
3 mm to 10 mm laterally of the sacral foramina S1-3 under
fluoroscopy. The correct depth of the needle was confirmed
laterally, after which 0.5 mL of 2% lidocaine was injected.
The dorsal ramus of L5 was also blocked as described in
the Spinal Intervention Society guidelines using 0.5 mL of
2% lidocaine.
The blocks were considered positive if the participant re-
ported 50% or more pain reduction within 30 to 90 minutes
after the block.
Thecurrentstandardfordiagnosingdiscogenicpain ispres-
sure-controlled provocative discography using strict criteria
and at least 1 negative control level.15
Randomization andMasking
Participants were randomized using a computerized random
number generator (Alea II, Netherlands Cancer Institute-
Antoni van Leeuwenhoek Hospital), accessed through a
password-protected website and maintained independently.
Randomization was performed at the individual level by
means of block randomization (block size = 4), prestratified
for pain clinic. Participants were allocated (1:1) to receive
either radiofrequency denervation with a standardized exer-
cise program (intervention group) or a standardized exercise
program alone (control group).
Participants and caregivers were not blinded. The Dutch
Ministry of Health,Welfare, and Sport requested a pragmatic
trial in which existing, commonly applied treatment options
would be compared. Data handling, analysis, and interpreta-
tion of results were conducted blind to treatment allocation.
All participants were sequentially assigned unique numbers.
Participants’ expectations and satisfaction16,17 were mea-
sured to evaluate a possible risk of bias due to a nonblinded
study design.
Interventions
Standardized Exercise Program
All participants received aprogrambasedon theDutchphysi-
cal therapy guidelines18 in 1 of 102 participating physical
therapypractices.The8- to 12-hourprograms focusedonqual-
ityofmovementandbehavior, andtookplaceduringa3-month
interventionperiod.Moredetails areavailable in thestudypro-
tocol,which is available in Supplement 1. If necessary, partici-
pants were referred to psychological care.
Radiofrequency Denervation
Within 1 week after the first exercise session the intervention
group received radiofrequencydenervation.The technical de-
tails of the radiofrequency denervation procedures are in-
cluded in the eAppendix in Supplement 2.19-22
Co-Interventions
In both treatment groups, participants were asked to refrain
from co-interventions during the intervention period of 3
months (duration of the standardized exercise program).
Co-interventions that were not allowed included (but were
not limited to) surgery; manual therapy; chiropractic therapy;
a change in current, back pain–related medication; or newly
prescribed medication. Analgesics were not prescribed, but
over-the-counter medication was allowed. Co-interventions
or recurrence of the radiofrequency denervation was allowed
after the intervention period of 3 months. These interven-
tions were recorded. Psychological care was not considered a
co-intervention and was provided when needed to partici-
pants in either treatment group.
Outcomes
The primary outcome was pain intensity, measured on an
11-point numerical rating scale (NRS; a score of 0 indicates no
pain; 10 indicates worst pain imaginable) 3 months after the
intervention.23
Secondary outcomes were global perceived recovery,16
participant satisfaction17 (both measured by the 7-point,
categorical Global Perceived Effect scale; a score of 1 indi-
cates fully recovered; 4 indicates no change; 7 indicates
worse than ever), functional status (measured by Oswestry
Disability Index [ODI]; a score of 0 indicates no restrictions in
daily activities; 100 indicates most restrictions in daily
activities),24 health-related quality of life (measured by the
3-level EuroQol 5D Health Questionnaire [EQ-5D-3L]; a score
of 0 indicates worst imaginable health state; 1 indicates best
imaginable health state),25 general health (measured by
RAND 36-Item Health Survey [Rand-36], a score of 0 indi-
cates lowest general health score; 100 indicates highest gen-
eral health score),26 and chronic pain experiences (measured
by the West Haven-Yale Multidimensional Pain Inventory; a
score of 0 indicates lowest score; 6 indicates highest score).27
Theminimal clinically importantdifference inpain forpar-
ticipantswith chronic lowbackpainwas estimated at 2points
or more of the 10-point NRS, a difference of 20 points on the
100-point ODI, and between 0.09 and 0.28 points on the
EQ-5D-3Lutility score between0and 1.28,29Nominimal clini-
cally important differences are known for the other second-
ary outcomes.
All outcome measures were registered using web-based
questionnaires,whichwere sent at baseline and3-, 6-, 9-, and
12-month follow-up. Pain intensity, global perceived recov-
ery, and health-related quality of life were also assessed at
3-week follow-up and 6-week follow-up.
Sample Size Calculation
A clinically relevant mean difference of 2 points or more on
the NRS28 for pain intensity (SD, 4) was used for the sample
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size calculation. With a power of 0.9, a 2-sided α of .05, and
a correlation of 0.5 for repeated measurements, 85 partici-
pants per group were needed. Anticipating potential study
withdrawal (20%), a minimum of 204 participants per trial
was needed.
Statistical Analyses
Effects were estimated using a maximum likelihood estima-
tion for longitudinal mixed-effects model, under “missing
at random” assumptions, including a term for pain clinic, if
necessary, based on the likelihood ratio test.30 We used a
generalized linear mixed model (logit link) for the post hoc
analysis of treatment response for dichotomized outcomes.
The same multilevel structure was used for both models. All
analyses were conducted in accordance with the intention-
to-treat principle.
Regression coefficients or odds ratios (ORs) with 95% CIs
were calculated; ORs were converted to relative risks (RRs)
using the method of Zhang et al31: RR = OR/[(1 − prevalence
in control group) + (prevalence in control group × OR)].
We adjusted for the outcome parameter at baseline, and age,
sex (self-reported), BMI, education, smoking, marital status,
back pain complaint history, and participant expectations.
The effect of interest was the time × treatment interaction.
Regression coefficients can be interpreted as mean differ-
ences between interventions compared with baseline. Addi-
tionally, we calculated the number needed to treat and the
unadjusted risk differences as absolute differences between
groups. Data were compared between complete and incom-
plete cases to identify possible selective dropout.
Treatment success for the global perceived recovery was
defined as “much recovery” or “complete recovery.” In post
hoc analyses, treatment success in pain reduction was de-
fined as either more than 30% or 2 points reduction or more
on the NRS pain scale.
No adjustments for multiple comparisons were made.
Findings for the secondary outcomes should be interpreted
as exploratory.
In 2 sensitivity analyses, participants marked as partici-
pants who had protocol violations, and participants who re-
ceived radiofrequencydenervationduring follow-upwere ex-
cluded from the analyses. Additionally, data were compared
between complete and incomplete cases. We used MLwiN
software (University of Bristol), version 2.22, for the effects
models (2-sided significance P < .05).
Results
In total, 251 patientswere included in the facet joint trial, 228
patients in the sacroiliac joint trial, and 202 in the combina-
tion trial (Figure 1, Figure 2, and Figure 3). The 681 random-
ized participants had a mean age of 52.2 years, 421 partici-
pants were women (61.8%), and the mean baseline pain
intensitywas 7.1 on theNRS scale. Another 5168patientswere
included in the observational part of Mint study.
Figure 1. Flow of Patients Through Enrollment in the 3 Randomized Clinical Trials
5168 Included in observational studya
2133 Asked to participate in the facet joint trial
1882 Excludedb
1202 Declined participation
52 BMI >35
93 Aged >70 y
258 Negative diagnostic facet joint block
277 Psychological problemsc
251 Randomized
See Figure 2
A
10 592 Potential participants
5424 Patients asked to participate in 1 of 3
trials based on suspected source of pain
2498 Asked to participate in the sacroiliac trial
2270 Excludedb
1666 Declined participation
47 BMI >35
83 Aged >70 y
15 Other
202 Negative diagnostic sacroiliac
joint block
257 Psychological problemsc
228 Randomized
See Figure 2
B
793 Asked to participate in the combination trial
591 Excludedb
298 Psychological problemsc
139 Other
52 BMI >35
102 Aged >70 y
202 Randomized
See Figure 3
C
BMI indicates bodymass index (calculated as weight in kilograms divided by
height in meters squared).
aObservational study was performed alongside randomized clinical trials;
results from the observational study are not reported in this article.
bParticipants not eligible for participation due to 1 positive exclusion criterion or
more could be included in the observational study.
c Participants were excluded based on psychological problems, assessed by
validated questionnaires.
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Figure 2. Flow of Patients Through the Facet Joint and Sacroiliac Joint Trials
117 Completed baseline visit
8 Did not complete baseline visit
3 Wrong contact information
4 No response
1 Died
116 Completed baseline visit
10 Did not complete baseline visit
4 Wrong contact information
5 No response
1 Unsure about participating
104 Completed baseline visit
8 Did not complete baseline visit
3 Wrong contact information
4 No response
1 Technical difficulties
109 Completed baseline visit
7 Did not complete baseline visit
2 Wrong contact information
5 No response
108 Completed 3-wk follow-up
17 Did not complete 3-wk follow-up
4 Wrong contact information
4 No response
1 Died
8 No treatment details
101 Completed 3-wk follow-up
25 Did not complete 3-wk follow-up
5 Wrong contact information
9 No response
1 Comorbidity
10 No treatment details
86 Completed 3-wk follow-up
26 Did not complete 3-wk follow-up
2 Wrong contact information
9 No response
3 Technical difficulties
10
2
No treatment details
Withdrewb
94 Completed 3-wk follow-up
22 Did not complete 3-wk follow-up
1 Wrong contact information
7 No response
14 No treatment details
119 Completed 6-wk follow-up
6 Did not complete 6-wk follow-up
2 Wrong contact information
2 No response
1 Died
1 No treatment details
118 Completed 6-wk follow-up
8 Did not complete 6-wk follow-up
1 Wrong contact information
5 No response
1 Comorbidity
1 No treatment details
107 Completed 6-wk follow-up
9 Did not complete 6-wk follow-up
1 Wrong contact information
7 No response
1 No treatment details
95 Completed 6-wk follow-up
17 Did not complete 6-wk follow-up
2 Wrong contact information
6 No response
3 Technical difficulties
3 No treatment details
3 Withdrewb
119 Completed 3-mo follow-up
6 Did not complete 3-mo follow-up
1 No internet
4 No response
1 Died
114 Completed 3-mo follow-up
12 Did not complete 3-mo follow-up
1 Wrong contact information
9 No response
1
1
No treatment details
Comorbidity
88 Completed 3-mo follow-up
24 Did not complete 3-mo follow-up
6 Wrong contact information
9 No response
3
6
Technical difficulties
Withdrewb
110 Completed 3-mo follow-up
6 Did not complete 3-mo follow-up
1 Wrong contact information
5 No response
113 Completed 6-mo follow-up
12 Did not complete 6-mo follow-up
2 Unmotivated
9 No response
1 Died
108 Completed 6-mo follow-up
18 Did not complete 6-mo follow-up
1 Wrong contact information
14 No response
1 Unsatisfied
1 No treatment details
1 Comorbidity
89 Completed 6-mo follow-up
23 Did not complete 6-mo follow-up
3 Wrong contact information
10 No response
3 Technical difficulties
7 Withdrewb
103 Completed 6-mo follow-up
13 Did not complete 6-mo follow-up
2 Wrong contact information
11 No response
103 Completed 12-mo follow-up
22 Did not complete 12-mo follow-up
3 No time
18 No response
1 Died
102 Completed 12-mo follow-up
24 Did not complete 12-mo follow-up
1 Wrong contact information
1 No treatment details
19 No response
2 Unmotivated
1 Comorbidity
77 Completed 12-mo follow-up
35 Did not complete 12-mo follow-up
3 Wrong contact information
19 No response
2 Technical difficulties
11 Withdrewb
101 Completed 12-mo follow-up
15 Did not complete 12-mo follow-up
1 Wrong contact information
12 No response
2 Withdrewb
106 Completed 9-mo follow-up
19 Did not complete 9-mo follow-up
1 Unmotivated
1 No internet
3 No time
13 No response
1 Died
78 Completed 9-mo follow-up
34 Did not complete 9-mo follow-up
3 Wrong contact information
19 No response
2 Technical difficulties
10 Withdrewb
105 Completed 9-mo follow-up
21 Did not complete 9-mo follow-up
1 Wrong contact information
18 No response
1 No treatment details
1 Comorbidity
101 Completed 9-mo follow-up
15 Did not complete 9-mo follow-up
1 Wrong contact information
12 No response
2 Withdrewb
125 Included in intention-to-
treat analysis
126 Included in intention-to-
treat analysis
116 Included in intention-to-
treat analysis
112 Included in intention-to-
treat analysis
116 Randomized to intervention group
110 Received radiofrequency
denervation as randomized
3 Received facet joint
radiofrequencya
3 Did not receive treatment
89 Completed exercise program
21 Did not complete exercise
program
6 Unknown completion
81 Received Palisade
radiofrequency treatment
23 Received cooled
radiofrequency denervation
6 Received SIMPLICITY III
denervation
125 Randomized to intervention group
121 Received radiofrequency
denervation as randomized
1 Did not receive treatment
101 Completed exercise program
18 Did not complete exercise
program
6 Unknown completion
3 Received sacroiliac joint
Palisade radiofrequency
treatmenta
112 Randomized to control group
69 Received exercise program
as randomized
18 Did not complete exercise
program
25 Unknown completion
126 Randomized to control group
92 Received exercise program
as randomized
22 Did not complete exercise
program
12 Unknown completion
Continued From Figure 1
251 Randomized
A
228 Randomized
BFacet joint trial Sacroiliac joint trial
a Participants received RF treatment other than their randomized assignment.
bStudy withdrawals were not cumulative.
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Figure 3. Flow of Patients Through the Combination Trial
98 Completed baseline visit
5 Did not complete baseline visit
1 Wrong contact information
2 No response
1 No complaints
1 Comorbidity
89 Completed baseline visit
10 Did not complete baseline visit
3 Wrong contact information
7 No response
77 Completed 3-wk follow-up
26 Did not complete 3-wk follow-up
1 Wrong contact information
4 No response
18 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
56 Completed 3-wk follow-up
43 Did not complete 3-wk follow-up
7 Wrong contact information
7 No response
29 No treatment details
90 Completed 6-wk follow-up
13 Did not complete 6-wk follow-up
1 Wrong contact information
3 No response
6 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
82 Completed 6-wk follow-up
17 Did not complete 6-wk follow-up
3 Wrong contact information
10 No response
4 No treatment details
88 Completed 3-mo follow-up
16 Did not complete 3-mo follow-up
1 Wrong contact information
8 No response
4 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
80 Completed 3-mo follow-up
19 Did not complete 3-mo follow-up
3 Wrong contact information
13 No response
3 No treatment details
85 Completed 6-mo follow-up
19 Did not complete 6-mo follow-up
1 Wrong contact information
12 No response
3 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
75 Completed 6-mo follow-up
24 Did not complete 6-mo follow-up
4 Wrong contact information
17 No response
3 No treatment details
80 Completed 9-mo follow-up
23 Did not complete 9-mo follow-up
3 Wrong contact information
13 No response
4 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
68 Completed 9-mo follow-up
31 Did not complete 9-mo follow-up
4 Wrong contact information
3 No treatment details
24 No response
77 Completed 12-mo follow-up
26 Did not complete 12-mo follow-up
3 Wrong contact information
16 No response
4 No treatment details
1 No complaints
1 Other treatment
1 Comorbidity
61 Completed 12-mo follow-up
38 Did not complete 12-mo follow-up
6 Wrong contact information
3 No treatment details
29 No response
103 Included in intention-to-treat analysis 99 Included in intention-to-treat analysis
Continued From Figure 1
202 Randomized
CCombination trial
99 Randomized to control group
71 Received exercise program as randomized
28 Did not complete exercise program
103 Randomized to intervention group
67 Received radiofrequency denervation
as randomized
67 Did not receive radiofrequency denervation
1 Positive diagnostic facet joint block
35 Negative diagnostic joint block
93 Completed exercise program
10 Did not complete exercise program
26 Positive facet joint block
21 Positive sacroiliac joint block
21 Positive facet and sacroiliac joint block
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Facet Joint Trial
Study Participants
Between January 1, 2013, and June 3, 2014 (the inclusion pe-
riod for the facet joint trial), 931 participants received a diag-
nostic facet joint block. Patients with a negative result for the
diagnostic facet joint block (n = 258) were excluded. Patients
with psychological problems (n = 277), older than 70 years
(n = 93), or with a BMI higher than 35 (n = 52) were followed
up in the observational study. The inclusion criteriaweremet
by 251 participants for the facet joint trial and were random-
ized to the intervention group (n = 125) and control group
(n = 126) (Figure 1 and Figure 2).
Baseline characteristics were comparable across groups
(Table 1). However, participants in the intervention grouphad
a first low back pain episode 12 years prior compared with 8
years prior in the control group.
Complete data on pain intensity, functional status, and
global perceived recovery after 3 months was obtained from
233 participants (93%). Complete outcome data on all fol-
low-uppoints during the yearwere obtained from 179partici-
pants (71%). Participantswith completedatawereolder,more
often nonsmokers, were more likely to have a partner, had a
higher BMI, andhad lowbackpain complaints for a longer pe-
riod (eTable 1 in Supplement 2).
Table 1. Baseline Characteristics of ParticipantsWith Chronic LowBack Pain
Characteristicsa
Facet Joint Trial Sacroiliac Joint Trial Combination Trial
Intervention
(n = 125)
Control
(n = 126)
Intervention
(n = 116)
Control
(n = 112)
Intervention
(n = 103)
Control
(n = 99)
Age, mean (SD), y 52.98 (11.48) 52.60 (10.79) 51.58 (10.94) 51.13 (12.22) 50.80 (11.33) 53.31 (10.35)
Women, No. (%) 65 (55.56) 60 (51.72) 87 (74.35) 79 (75.96) 64 (65.31) 66 (74.15)
BMI, mean (SD) 26.77 (5.17) 27.62 (4.27) 26.73 (4.17) 26.76 (4.53) 26.84 (3.82) 26.43 (4.25)
Smoker, No. (%) 34 (29.05) 34 (29.05) 29 (26.61) 31 (29.81) 23 (23.46) 26 (29.21)
Education level, No. (%)b
Low 57 (48.72) 64 (55.17) 59 (54.13) 53 (50.96) 52 (53.06) 43 (48.31)
Moderate 35 (29.99) 34 (29.31) 32 (29.36) 32 (30.76) 33 (33.67) 32 (35.96)
High 21 (17.95) 16 (13.79) 18 (16.51) 18 (17.31) 12 (12.24) 14 (15.73)
Married or living with a
partner, No. (%)
93 (79.49) 98 (84.48) 85 (79.61) 82 (79.61) 66 (67.35) 68 (76.40)
Having a paid job, No. (%) 64 (54.70) 66 (56.80) 66 (60.55) 50 (48.07) 48 (48.97) 44 (48.44)
History of back pain,
median (IQR), mo
Time since first
experience with
low back pain
146.00
(49.75-267.67)
100.33
(36.5-186.30)
97.33
(37.51-228.12)
65.08
(27.08-144.21)
120.58
(37.32-222.04)
97.33
(32.33-192.58)
Time since first
current episode with
low back pain
31.33
(12.17-103.42)
26.73
(10.54-73.00)
30.33
(12.17-76.03)
24.33
(12.17-66.58)
36.50
(12.17-121.67)
32.33
(8.00-97.19)
Origin of back pain, No.
Facet and sacroiliac joint 69 70
Facet and disc 18 18
Sacroiliac joint and disc 6 1
Facet and sacroiliac
joint and disc
3 6
Unknown 7 4
CEQ score, mean (SD)c
Credibility 21.36 (3.92) 19.47 (5.49) 21.36 (4.51) 19.88 (5.31) 20.10 (4.70) 17.07 (5.99)
Expectancy 18.97 (4.59) 17.36 (5.20) 18.75 (4.99) 18.23 (5.31) 16.88 (5.78) 14.38 (6.24)
Pain intensity score in the
past week, mean (SD)d
7.14 (1.38) 7.19 (1.29) 7.17 (1.65) 7.06 (1.43) 7.19 (1.43) 7.43 (1.41)
Functioning score,
mean (SD)e
35.07 (14.66) 34.39 (12.24) 38.07 (14.07) 33.70 (14.43) 39.06 (14.03) 37.20 (13.74)
Quality-of-life score,
mean (SD)f
0.52 (0.26) 0.54 (0.26) 0.50 (0.27) 0.56 (0.27) 0.49 (0.28) 0.52 (0.28)
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); CEQ, credibility expectancy questionnaire.
a Results are presented of the 233 participants in the facet joint trial,
207 participants in the sacroiliac joint trial, and 187 participants in the
combination trial who had complete baseline data.
bEducation levels: low indicates preschool, primary school, or lower secondary
school; moderate indicates higher secondary school or undergraduate; high
indicates tertiary, university, or postgraduate.
c A higher score indicates more credibility in the effectiveness of treatment or
higher expectations about the treatment (score range, 0-27).
dMeasured by numeric rating scale (score range, 0-10); a higher score indicates
more severe pain intensity.
eMeasured by Oswestry Disability Index (score range, 0-100); a higher score
indicates worse functioning.
f Measured by EuroQol-5D (score range, 0-1); a higher score indicates better
quality of life.
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Twelve participants in the control group received radio-
frequency denervation within the first 3 months and were
marked as participants who had protocol violations. Ten par-
ticipants (8%) in the interventiongroupand11participants (9%)
in the control group received psychological care during the
3-month intervention period.
No treatment-related adverse events were reported dur-
ing the 1-year follow-up.
Intention-to-Treat Analyses
The mean difference for the primary outcome pain intensity
at 3 months was −0.18 (95% CI, −0.76 to 0.40). Results on all
other follow-up points are shown in Table 2 and Table 3. The
mean difference for functional status at 3 months was −2.45
(95% CI, −5.53 to 1.03); the RR for global perceived recovery
at 3 months was 1.35 (95% CI, 0.81 to 2.05). Other follow-up
points and secondary outcomes are shown in eTable 2 in
Supplement 2.
Post Hoc Analyses of Treatment Response
No significant differences between the groups were found
when success was defined as more than 30% or 2 points re-
duction or more in pain at 3 months (Table 4).
Sensitivity Analyses
When participants with protocol violations were excluded
from the analysis, the interpretation of the outcomes
remained similar (eTable 3 in Supplement 2). After 3 months
of follow–up, 31 control group participants received radiofre-
quency denervation. The analyses were repeated excluding
participants receiving the intervention after the 3-month
intervention period; this did not alter the results either
(eTable 4 in Supplement 2). The complete case analysis
showed no significant between-group differences for pain
intensity, functional status, and global perceived recovery at
3 months (eTable 5 in Supplement 2).
Sacroiliac Joint Trial
Study Participants
Between January 1, 2013, and July 1, 2014 (the inclusion
period for the sacroiliac joint trial), 832 participants received
a diagnostic sacroiliac joint block. Patientswith a negative re-
sult for the diagnostic sacroiliac joint block (n = 202) were
excluded. Patients with psychological problems (n = 257),
older than 70 years (n = 83), or a BMI higher than 35 (n = 47),
or other reasons for not participating in the trial (n = 15) were
followed up in the observational study. The inclusion criteria
were met by 228 participants for the sacroiliac joint trial and
were randomized to the intervention group (n = 116) and the
control group (n = 112) (Figure 1 and Figure 2).
Baseline characteristics were comparable across groups
(Table 1).However, the first episodeof lowbackpain in the in-
tervention group was 97 months before inclusion compared
with 65 months in the control group.
Table 2. Pain Intensity Score (Primary Outcome)a,bAmong ParticipantsWith Chronic LowBack Pain
Overall Effect
Intervention Group,
Mean (95% CI)
Control Group,
Mean (95% CI)
Between-Group Difference,
Mean (95% CI)c P Value
Facet joint trial,
No. of participants
125 126
Overall −0.08 (−0.50 to 0.34) .71
3 wk 5.17 (4.73 to 5.61) 5.92 (5.58 to 6.26) −0.41 (−1.02 to 0.19) .18
6 wk 5.19 (4.76 to 5.61) 5.90 (5.53 to 6.26) −0.38 (−0.96 to 0.20) .20
3 mo 5.01 (4.59 to 5.43) 5.44 (5.03 to 5.85) −0.18 (−0.76 to 0.40) .55
6 mo 4.61 (4.18 to 5.04) 4.84 (4.38 to 5.30) −0.04 (−0.63 to 0.56) .91
9 mo 4.66 (4.20 to 5.00) 4.73 (4.24 to 5.22) 0.19 (−0.41 to 0.80) .53
12 mo 4.49 (4.00 to 4.97) 4.44 (3.94 to 4.94) 0.47 (−0.14 to 1.07) .13
Sacroiliac joint trial,
No. of participants
116 112
Overall −0.40 (−0.83 to 0.03) .07
3 wk 4.96 (4.51 to 5.40) 6.00 (5.59 to 6.41) −0.96 (−1.63 to −0.29) .005
6 wk 5.22 (4.81 to 5.64) 5.69 (5.31 to 6.08) −0.53 (−1.17 to 0.10) .10
3 mo 4.77 (4.31 to 5.24) 5.45 (4.94 to 5.95) −0.71 (−1.35 to −0.06) .03
6 mo 4.50 (4.01 to 4.98) 4.78 (4.24 to 5.31) −0.12 (−0.77 to 0.53) .73
9 mo 5.03 (4.55 to 5.51) 4.97 (4.39 to 5.56) 0.16 (−0.51 to 0.83) .64
12 mo 4.65 (4.16 to 5.13) 4.84 (4.30 to 5.38) −0.07 (−0.74 to 0.60) .83
Combination trial,
No. of participants
103 99
Overall −0.21 (−0.76 to 0.35) .47
3 wk 5.45 (4.95 to 5.95) 6.40 (5.91 to 6.89) −0.65 (−1.47 to 0.17) .12
6 wk 5.37 (4.89 to 5.85) 6.09 (5.65 to 6.52) −0.40 (−1.14 to 0.34) .29
3 mo 4.77 (4.25 to 5.30) 5.94 (5.42 to 6.45) −0.99 (−1.73 to −0.25) .01
6 mo 4.92 (4.39 to 5.44) 4.95 (4.35 to 5.54) 0.33 (−0.53 to 1.09) .39
9 mo 5.01 (4.47 to 5.56) 5.25 (4.65 to 5.86) −0.05 (−0.82 to 0.73) .90
12 mo 4.85 (4.24 to 5.46) 4.38 (3.73 to 5.03) 0.69 (−0.10 to 1.49) .09
Abbreviation: NNT, number needed
to treat.
aMeasured by numeric rating scale
(score range, 0-10); a higher score
indicates more severe symptoms.
bThe overall effect measures provide
information over the total follow-up
time of 12 mo, instead of the
time × treatment effects.
c Values presented (for mean
differences) are model estimates of
linear mixed-effects models with a
random intercept, and adjusted for
outcome at baseline and age, sex,
bodymass index, education,
smoking, marital status, back pain
complaint history, and participant
expectations. Regression
coefficients can be interpreted as
mean differences between
interventions at a certain follow-up
point compared with baseline.
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Table 3. Secondary Outcomes Among ParticipantsWith Chronic LowBack Paina
Overall Effect
Intervention Group,
Mean (95% CI)
Control Group,
Mean (95% CI)
Between-Group
Difference,
Mean (95% CI)b P Value
Risk Difference
(95% CI) NNT
Functioning Scorec,d
Facet joint trial,
No. of participants
125 126
Overall 0.04 (−3.02 to 3.10) .98
3 mo 26.03 (23.01 to 29.06) 28.67 (26.06 to 31.84) −2.45 (−5.93 to 1.03) .17
6 mo 25.38 (22.45 to 28.30) 27.15 (24.07 to 30.23) −0.60 (−4.13 to 2.92) .74
9 mo 25.74 (22.74 to 28.73) 24.52 (21.49 to 27.54) 2.26 (−1.29 to 5.82) .21
12 mo 24.59 (21.39 to 27.79) 25.04 (21.77 to 28.31) 1.48 (−2.09 to 5.06) .42
Sacroiliac joint trial,
No. of participants
116 112
Overall 0.42 (−2.99 to 3.82) .81
3 mo 27.72 (24.50 to 30.95) 29.09 (25.47 to 2.71) −4.20 (−8.39 to −0.00) .05
6 mo 25.99 (22.91 to 29.05) 24.99 (21.45 to 28.52) 0.07 (−4.16 to 4.30) .97
9 mo 28.40 (25.05 to 31.75) 23.45 (20.00 to 6.91) 4.45 (0.14 to 8.77) .04
12 mo 27.29 (23.89 to 30.69) 24.49 (20.74 to 28.23) 2.11 (−2.25 to 6.47) .34
Combination trial,
No. of participants
103 99
Overall 1.90 (−2.96 to 6.76) .44
3 mo 28.00 (24.65 to 31.35) 33.63 (29.88 to 37.37) −4.66 (−10.21 to 0.89) .10
6 mo 30.24 (26.14 to 34.34) 28.61 (24.80 to 32.43) 4.44 (−1.18 to 0.06) .12
9 mo 30.73 (26.83 to 34.63) 28.70 (24.48 to 32.91) 3.55 (−2.17 to 9.26) .22
12 mo 31.20 (27.20 to 35.20) 24.67 (20.88 to 28.45) 6.44 (0.61 to 12.26) .03
Global Perceived Recoverye
No. With Treatment
Success/Total No. (%)
No. With Treatment
Success/Total No. (%)
Relative Risk
(95% CI)f
P Value Risk Difference
(95% CI)
NNT
Facet joint trial,
No. of participants
125 126
3 wk 32/108 (29.63) 5/101 (4.95) 5.41 (2.29 to 10.34) <.001 24.68 (15.08 to 34.27) 4
6 wk 35/119 (29.41) 11/118 (9.32) 2.71 (1.37 to 4.68) .005 20.09 (10.37 to 29.81) 5
3 mo 43/119 (36.13) 27/114 (23.68) 1.35 (0.81 to 2.05) .24 12.45 (0.81 to 24.09) 8
6 mo 46/113 (40.70) 39/108 (36.11) 1.04 (0.64 to 1.12) .85 4.59 (−8.21 to 17.41) NA
9 mo 41/106 (38.67) 42/105 (40.00) 0.81 (0.48 to 0.57) .35 −1.33 (−14.50 to 11.86) NA
12 mo 44/103 (42.71) 40/102 (39.22) 0.90 (0.55 to 1.33) .65 3.49 (−9.95 to 16.96) NA
Sacroiliac joint trial,
No. of participants
116 112
3 wk 28/94 (29.78) 9/88 (10.23) 2.83 (1.39 to 4.89) .01 19.55 (8.35 to 30.77) 5
6 wk 43/110 (39.09) 10/95 (10.53) 3.71 (2.00 to 5.74) <.001 28.56 (17.55 to 39.58) 4
3 mo 43/110 (39.10) 19/88 (21.59) 1.87 (1.13 to 2.71) .02 17.51 (4.97 to 30.03) 6
6 mo 46/103 (44.66) 29/88 (32.95) 1.26 (0.83 to 1.84) .21 11.71 (−2.03 to 25.44) NA
9 mo 36/101 (35.64) 25/78 (32.05) 1.13 (0.67 to 1.70) .62 3.59 (−10.35 to 17.54) NA
12 mo 49/102 (48.03) 24/76 (31.78) 1.46 (0.92 to 2.02) .10 16.25 (2.20 to 30.72) NA
Combination trial,
No. of participants
103 99
3 wk 17/77 (22.07) 4/56 (7.14) 2.23 (0.73 to 5.52) .15 14.93 (3.48 to 25.40) 6
6 wk 25/90 (27.77) 7/82 (8.54) 2.41 (0.99 to 4.90) .05 19.23 (8.19 to 30.30) 5
3 mo 30/88 (34.09) 13/80 (16.25) 1.99 (0.99 to 3.37) .06 17.84 (5.06 to 30.63) 5
6 mo 30/85 (35.29) 28/75 (37.33) 0.76 (0.39 to 1.30) .36 −2.04 (−16.97 to 12.90) NA
9 mo 29/82 (35.36) 21/68 (30.88) 1.11 (0.57 to 1.82) .73 4.48 (−10.61 to 19.57) NA
12 mo 26/75 (34.66) 22/61 (36.06) 0.91 (0.46 to 1.52) .76 −1.40 (−17.65 to 14.76) NA
Abbreviations: NA, not applicable; NNT, number needed to treat.
a The other secondary outcomes are presented in eTable 2 in Supplement 2.
bValues presented (for mean differences) are model estimates of linear
mixed-effects models with a random intercept, and adjusted for outcome
at baseline and age, sex, bodymass index, education, smoking, marital status,
back pain complaint history, and participant expectations. Regression
coefficients can be interpreted as mean differences between interventions
at a certain follow-up point compared with baseline.
cMeasured by Oswestry Disability Index (score range, 0-100); a higher score
indicates worse functioning.
dThe overall effect measures provide information over the total follow-up time
of 12 mo, instead of the time × treatment effects.
eMeasured by the Global Perceived Effect scale (range, 1-7); a score of 1 to 2
indicates success.
f Relative risk was estimated based on themethod of Zhang et al.31
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Table 4. Successful Treatment Effects for Pain Intensity by Study Among ParticipantsWith Chronic LowBack Pain
Intervention Group,
No.With Treatment
Success/Total No. (%)
Control Group,
No. With Treatment
Success/Total No. (%)
Relative Risk
(95% CI)a P Value
Risk Difference
(95% CI) NNT
Facet Joint Trial
Pain intensity
reduction >30%
3 wk 40/102 (39.22) 27/100 (27.00) 1.33 (0.80 to 1.97) .25 12.22 (−0.65 to 25.08) NA
6 wk 45/112 (40.17) 36/114 (31.57) 1.13 (0.70 to 1.63) .59 8.60 (−3.86 to 21.06) NA
3 mo 52/114 (45.61) 40/111 (36.03) 1.16 (0.76 to 1.60) .46 9.58 (−3.20 to 22.36) NA
6 mo 60/108 (55.56) 53/105 (50.47) 1.02 (0.71 to 1.33) .88 5.09 (−8.31 to 18.47) NA
9 mo 52/102 (50.98) 50/102 (49.02) 1.09 (0.75 to 1.42) .60 1.88 (−11.76 to 15.68) NA
12 mo 47/100 (47.00) 53/99 (53.53) 0.78 (0.50 to 1.09) .16 −6.53 (−20.40 to 7.33) NA
Pain intensity
reduction ≥2 points
3 wk 56/102 (54.90) 44/100 (44.00) 1.17 (0.81 to 1.53) .36 10.90 (−2.81 to 24.61) NA
6 wk 57/112 (50.89) 47/114 (41.23) 1.09 (0.74 to 1.46) .65 9.66 (−3.27 to 22.60) NA
3 mo 64/111 (57.65) 52/111 (46.85) 1.07 (0.75 to 1.39) .68 10.80 (−2.25 to 23.87) NA
6 mo 68/108 (62.96) 61/105 (58.09) 1.00 (0.73 to 1.25) .98 4.84 (−8.25 to 17.98) NA
9 mo 56/102 (54.90) 58/102 (56.86) 0.90 (0.62 to 1.17) .47 −1.96 (−15.59 to 11.66) NA
12 mo 55/100 (55.00) 55/99 (55.56) 0.76 (0.49 to 1.05) .11 −0.56 (−14.37 to 13.26) NA
Sacroiliac Joint Trial
Pain intensity
reduction >30%
3 wk 41/90 (45.56) 16/83 (19.27) 2.35 (1.45 to 3.32) .001 26.29 (12.94 to 39.62) 4
6 wk 43/104 (41.35) 25/91 (27.47) 1.49 (0.94 to 2.18) .08 13.88 (0.69 to 27.05) 7
3 mo 48/105 (45.71) 29/84 (34.52) 1.33 (0.87 to 1.81) .16 11.19 (−2.74 to 25.13) NA
6 mo 50/99 (50.51) 42/85 (49.41) 1.01 (0.69 to 1.34) .94 1.10 (−13.40 to 15.58) NA
9 mo 39/98 (39.79) 33/76 (43.42) 0.88 (0.54 to 1.27) .53 −3.63 (−18.39 to 11.14) NA
12 mo 48/97 (49.48) 31/75 (41.33) 1.15 (0.75 to 1.56) .48 8.15 (−6.79 to 23.09) NA
Pain intensity
reduction ≥2 points
3 wk 56/90 (62.22) 30/83 (36.14) 1.68 (1.25 to 2.05) .002 26.08 (11.68 to 40.47) 4
6 wk 59/104 (56.73) 40/91 (43.95) 1.29 (0.97 to 1.59) .08 12.78 (−1.18 to 26.73) NA
3 mo 62/105 (59.05) 40/84 (47.61) 1.25 (0.94 to 1.52) .11 11.44 (−2.80 to 25.66) NA
6 mo 61/99 (61.61) 47/85 (55.29) 1.12 (0.85 to 1.35) .37 6.32 (−7.94 to 20.59) NA
9 mo 51/98 (52.04) 41/76 (53.95) 0.96 (0.68 to 1.22) .76 −1.91 (−16.85 to 13.04) NA
12 mo 57/97 (58.76) 41/75 (54.67) 1.04 (0.76 to 1.30) .77 4.09 (−10.83 to 19.03) NA
Combination Trial
Pain intensity
reduction >30%
3 wk 23/75 (30.67) 7/48 (14.58) 2.39 (1.08 to 4.16) .03 16.09 (1.64 to 30.53) 6
6 wk 32/88 (36.36) 21/72 (29.17) 1.16 (0.63 to 1.84) .60 7.19 (−7.34 to 21.73) NA
3 mo 43/86 (50.00) 19/72 (26.38) 1.92 (1.19 to 2.65) .01 23.62 (8.94 to 38.28) 4
6 mo 36/82 (43.90) 38/68 (55.88) 0.77 (0.44 to 1.11) .19 −11.98 (−27.94 to 3.98) NA
9 mo 38/81 (46.91) 26/61 (42.62) 1.05 (0.62 to 1.52) .83 4.29 (−12.21 to 20.79) NA
12 mo 37/75 (49.33) 32/56 (57.14) 0.86 (0.52 to 1.21) .47 −7.81 (−25.02 to 9.40) NA
Pain intensity
reduction ≥2 points
3 wk 32/75 (42.67) 12/48 (25.00) 1.67 (0.89 to 2.57) .10 17.67 (1.04 to 34.26) 5
6 wk 44/88 (50.00) 33/72 (45.83) 0.96 (0.58 to 1.37) .83 4.17 (−11.38 to 19.71) NA
3 mo 48/86 (55.81) 28/72 (38.88) 1.32 (0.85 to 1.79) .20 16.93 (1.53 to 32.32) 5
6 mo 49/82 (59.76) 43/68 (63.23) 0.91 (0.59 to 1.19) .54 −3.47 (−19.10 to 12.14) NA
9 mo 48/81 (59.25) 34/61 (55.73) 0.98 (0.62 to 1.31) .91 3.52 (−12.91 to 19.95) NA
12 mo 41/75 (54.67) 37/56 (66.07) 0.80 (0.50 to 1.10) .21 −11.40 (−28.16 to 5.35) NA
Abbreviations: NA, not applicable; NNT, number needed to treat.
a Relative risk was estimated based on themethod of Zhang et al.31
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Complete data on pain intensity, functional status, and
global perceived recovery after 3monthswere obtained from
198 participants (87%). Complete outcome data on all fol-
low-uppoints during the yearwere obtained from 134partici-
pants (59%). The participantswith complete datawere older,
more often nonsmokers, were more likely to have a partner,
and had low back pain complaints for a longer period (eTable
1 in Supplement 2).
Sevenparticipants in the control group received radiofre-
quencydenervationwithin the first 3monthsandweremarked
as participants who had protocol violations. Seven partici-
pants (6%) in the intervention group and 6 participants (5%)
in the control group received psychological care during the
3-month intervention period.
Therewas 1 registered treatment-relatedcomplication (va-
sovagal reaction to treatment).
Intention-to-Treat Analyses
The mean difference for the primary outcome pain intensity
at 3months was −0.71 (95% CI, −1.35 to −0.06). Results on all
other follow-up points are shown in Table 2 and Table 3. The
mean difference for functional status at 3 months was −4.20
(95% CI, −8.39 to −0.002); the RR for global perceived recov-
ery at 3 months was 1.87 (95% CI, 1.13 to 2.71). Other fol-
low-up points and secondary outcomes are shown in eTable
2 in Supplement 2.
Post Hoc Analyses of Treatment Response
No significant differences between the groups were found
when success was defined as more than 30% or 2 points re-
duction or more in pain at 3 months (Table 4).
Sensitivity Analyses
When participants who had protocol violations were
excluded from the analysis, the interpretation of the out-
comes remained similar (eTable 3 in Supplement 2). After
3 months of follow–up, 41 control group participants re-
ceived radiofrequency denervation. Excluding these from the
analysis did not change the long-term results (eTable 4 in
Supplement 2). The complete case analysis showed no sig-
nificant between-group differences for the primary outcomes
at 3 months than participants without complete data (eTable
5 in Supplement 2).
Combination Trial
Study Participants
Between January 1, 2013, andOctober 24, 2014 (the inclusion
period for participants in this trial), 793 participants were eli-
gible for this trial. The inclusion criteriaweremet by 202 par-
ticipants, and those participants were randomly assigned to
the intervention (n = 103) and control group (n = 99). All rea-
sons for exclusions are presented in the flow charts (Figure 1
and Figure 3).
Baseline characteristics were comparable in both groups
(Table 1).
Complete data on pain intensity, functional status, and
global perceived recovery after 3 months were obtained
from 168 participants (83%). Complete data on all follow-up
assessments were obtained from 89 participants (44%) on
the effect measures. Participants with complete data had
low back pain complaints for a longer period, but were simi-
lar for all other demographic characteristics (eTable 1 in
Supplement 2).
Two participants in the control group received radiofre-
quency denervation, and 2 participants did not receive any
treatment. In the intervention group, 11 participants did not
receive or it was unknown if they received the standardized
exercise program. These 14 participantswere consideredpar-
ticipantswhohadprotocol violations. Eight participants (8%)
in the interventiongroupand 10participants (10%) in the con-
trol group receivedpsychological care during the 3-month in-
tervention period.
In the intervention group, 35 participants had negative
results for diagnostic blocks and did not receive radiofre-
quency denervation. These participants were still included
in the intention-to-treat analyses. The diagnostic block had
a positive result for 68 participants, of whom 25 received
facet joint radiofrequency denervation, 21 sacroiliac joint
radiofrequency denervation, 21 received a combination
of radiofrequency denervation treatments (facet and sacro-
iliac joint radiofrequency denervation), and 1 participant did
not receive radiofrequency denervation despite a positive
result for the diagnostic block.
Onecomplicationwas recordedduring the1-year follow-up
in the intervention group: a hematoma, causing extra pain.
The participant completely recovered.
Intention-to-Treat Analyses
The mean difference for the primary outcome pain intensity
at 3months was −0.99 (95%CI, −1.73 to −0.25). Results on all
other follow-up points are shown in Table 2 and Table 3. The
mean difference for functional status at 3 months was −4.66
(95%CI, −10.21 to 0.89); the RR for global perceived recovery
at 3 months was 1.99 (95% CI, 0.99 to 3.36). Other follow-up
points and secondary outcomes are shown in eTable 2 in
Supplement 2.
Post Hoc Analyses of Treatment Response
When success was defined as 30% pain reduction (RR, 1.92
[95%CI, 1.19 to 2.65]), therewas a statistically significant dif-
ference at 3months favoring the intervention group (Table 4).
Sensitivity Analyses
Excluding participants who had protocol violations from the
analysis slightly increased the contrast between the groups,
as significantly more people in the intervention group recov-
ered based on global perceived recovery after 3 months
(RR, 2.07 [95% CI, 1.02 to 3.43]) (eTable 3 in Supplement 2).
After 3 months follow-up, 31 control group participants
received radiofrequency denervation. The analyses were
repeated without participants receiving the intervention
after the 3-month intervention period; this resulted in only
minor differences (eTable 4 in Supplement 2). The complete-
cases analysis showed no significant between-group differ-
ences for the primary outcomes at 3 months (eTable 5 in
Supplement 2).
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Discussion
In 3 trials, the effects of radiofrequency denervation for par-
ticipants with chronic low back pain due to facet joints, sac-
roiliac joints, or a combination of the facet joints, sacroiliac
joints, or intervertebral disks in addition to a standardized ex-
ercise program were compared with a standardized exercise
program alone. The 2 trials assessing radiofrequency dener-
vation for the sacroiliac joints and a combination of the facet
joints, sacroiliac joints, or intervertebral disks showed a sta-
tistically significant but not clinically important improve-
ment inpain intensity3monthsafter the intervention.Noclini-
cally important or statistically significantdifferencesbetween
the groups were shown in the trial assessing radiofrequency
denervation for facet joint pain. Only small or no effectswere
found for all secondary outcomes.
Basedonthis study, radiofrequencydenervation isnot rec-
ommended and should be performed only in a research set-
ting. Patients with chronic low back pain who show no im-
provement in symptomsafter conservative treatmenthaveno
clear alternative therapies that have been shown to be effec-
tive.Future research regarding thediagnosis and treatment for
lowbackpain inparticipantswithchronic lowbackpain isnec-
essary and should focus on better participant selection (be-
cause there remains a possibility that radiofrequency dener-
vation could be beneficial on a subset of participants) and
improvement of the treatment techniques.
Strengths and Limitations
Strengths of these trials are the large sample sizes and strati-
fied randomization that allowed for well-balanced study
groups, and theuseof outcomemeasures as recommendedby
the core outcome set for lowback pain research.32 In addition
to theprimary timepoint at 3months, a follow-upof 12months
was included.
This studyhas several limitations.First, different radiofre-
quencydenervation techniques (cooled radiofrequencydener-
vation, Palisade, and Simplicity III) were used in the sacroiliac
joint trial.33-36 However, the groups were too small for a sub-
groupanalysis.Second,becausetheaimof thestudywastopro-
vide evidence of the added value of radiofrequency denerva-
tion in a multidisciplinary setting, as done in daily practice,
participants and clinicians were not blinded. Evidence sug-
gests that treatment effects for subjective outcomes may
be overestimated when outcome assessors (ie, participants, if
outcomes are self-reported) are not blinded.37 However, the
magnitude of this bias is unknown. The lack of blinding was a
significant limitation of the trials, and it is possible that radio-
frequency denervation could even be harmful, but the lack of
blindingmay havemade the treatment effect seem null. Also,
theshort-termdifferences inglobalperceivedrecovery for facet
joint and sacroiliac joint radiofrequency denervation in ab-
sence of a difference in functional statusmight be the result of
a nonspecific effect due to the nonblinded study design.
Third,a referencestandard fordiagnosing facet jointor sac-
roiliac joint pain is not available.14 In this pragmatic study, di-
agnostic tests that are commonly applied in clinical practice
were used. Controversy concerning the ideal threshold value
of pain reduction in the diagnostic blocks exists. A 50% cut-
offwasmost frequentlyused inprevious studies38and inclini-
cal practice. Performing 2 or more independent diagnostic
blocks will decrease the false-positive rate, but increase the
numberof false-negativeblocks.38Furthermore, a clinical trial
showed that multiple blocks are not cost-effective.38
Fourth, thegeneralizabilityof the resultsmightbe reduced
by the largenumberofpeopleexcluded forpsychologicalprob-
lems. In theNetherlands,participantsvisitingapainclinicoften
have long-lasting persistent low back pain. A large number of
theseparticipantshavepsychological problems.Thesepartici-
pants were excluded from this study because in daily practice
theyarenotconsideredcandidates for radiofrequencydenerva-
tion andwill be referred to psychological treatment.
Fifth, in all 3 trials, some control group participants re-
ceived radiofrequency denervation after the 3-month inter-
vention period (25% in the facet joint trial, 35% in sacroiliac
joint trial, and 31% in the combination trial) and some inter-
vention group participants received a second radiofrequency
denervation (8% in the facet joint trial, 17% in the sacroiliac
joint trial, and 15% in the combination trial). This could have
influencedthe long-termoutcomes.However, sensitivityanaly-
ses without these participants showed similar results.
Sixth, in the sacroiliac joint trial, therewas a higher drop-
out in thecontrol group.This couldpotentiallyhavebiased the
long-term results.
Seventh, in the combination trial, not all participants in
the intervention group received radiofrequency denerva-
tion, because they did not respond to the diagnostic block or
provocative discography.
Eighth, more missing data were found in the combina-
tion trial compared with the other 2 trials. This is a potential
limitation, but because of the relatively large number of
dropouts at 12 months, the complete case analysis might also
be biased. Although we did not define differences between
the complete-case analysis and the intention-to-treat analy-
sis using all data, it is possible that completers are different
from noncompleters, which could have biased the results of
the complete-case analyses.
Ninth, we assessed multiple outcomes and made no ad-
justment for multiple comparisons, which could have re-
sulted in some statistically significant findings by chance.
ComparisonWith the Literature
Recent systematic reviews have evaluated the association of
radiofrequency denervation with isolated pain sources and
showed evidence of low to moderate quality for associations
of facet joint radiofrequency with small positive effects on
pain and functional status compared with placebo or steroid
injections.9-11 There is very low tomoderate quality evidence
andconflictingevidence for sacroiliac joint radiofrequencyde-
nervation and radiofrequency denervation in the interverte-
bral disk.5,9-11 In the trials included in these reviews, partici-
pantshadabaselinepain scoreof 1 point lower comparedwith
this trial, and the radiofrequency denervation groups de-
creased more (to 3.3 of 10) than the placebo groups (to 5.0 of
10). In the Mint study, participants in both groups decreased
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in pain, but both groups continued to have a higher pain level
compared with other similar trials.
Conclusions
In 3 randomized clinical trials of participants with chronic
low back pain originating in the facet joints, sacroiliac
joints, or a combination of facet joints, sacroiliac joints, or
intervertebral disks, radiofrequency denervation combined
with a standardized exercise program resulted in either no
improvement or no clinically important improvement in
chronic low back pain compared with a standardized exer-
cise program alone. The findings do not support the use of
radiofrequency denervation to treat chronic low back pain
from these sources.
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SUMMARY 
 
Rationale: Low back pain is a common complaint associated with high costs. Minimal 
interventional procedures are frequently applied in pain clinics in a subgroup of patients with 
chronic low back pain, namely in patients with pain resulting from single sources: facet, 
discus, sacroiliac joint or a combination of these. There is no general accepted definition 
and/or classification of these kinds of complaints. The terminology, which is used in the 
reimbursement system (DBC system) of the Dutch Anaesthesiology Society, is a 
classification of mechanical, neurologic and sympathic. Mechanical low back pain is defined 
as pain resulting from single sources: facet, discus, sacroiliac joint or a combination of these. 
In the proposal we use the terminology in this way. These minimal interventional procedures 
are nowadays performed in pain clinics in a multidisciplinary setting for diagnosis and 
therapy. Treatment with minimal interventional procedures is used as a part of a 
multidisciplinairy pain programme. A recent systematic review issued by the Dutch Health 
Insurance Council (CVZ 26/3/2011) showed that the effectiveness of minimal interventional 
procedures for the total group of chronic low back pain is unclear and the cost-effectiveness 
unknown. Based on these studies CVZ has decided not to include these procedures in our 
public health insurance. Despite the fact that the evidence for effectiveness of minimal 
interventional procedures also for specific subgroups like mechanical low back pain is 
limited, these procedures are, based on a risk benefit balance, recommended in the practical 
anaesthesiology guidelines for pain treatment and frequently applied in daily practice.  
 
Objective: The aim of this study is to evaluate whether a multidisciplinary pain programme 
with minimal interventional procedures is effective and cost-effective compared with the 
multidisciplinary pain programme alone for patients with mechanical low back pain who did 
not respond to conservative primary care and were referred to a pain clinic. 
 
Study design: We will conduct three clinical and economic evaluations from a societal 
perspective in which the single entities of mechanical low back pain and a mix of the single 
entities will be studied. Besides, we will perform an observational study of the total turnover 
of not eligible patients in pain clinics. Outcome measures are pain intensity, recovery, 
functional status and costs. Both a cost-effectiveness and cost-utility analysis will be 
performed. 
 
Study population: We will include patients with mechanical low back pain who are referred 
by a general practitioner or medical specialist to participating pain clinics.  
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Intervention: In the diagnostic phase, patients will be selected by making use of diagnostic 
criteria as described in the Guideline low back pain (NVA, NVvN et al. 2011). 
Based on signs and symptoms, patients with suspicion of a single entity, namely pain arising 
from the facet joints or sacroiliac joint will receive a test block with local anaesthetics. 
Patients with the suspicion of pain arising from a disc will receive a provocative discography. 
,ISDWLHQWVDQVZHU\HVWRWKHTXHVWLRQµLVWKHUHDRUPRUHUHGXFWLRQ LQSDLQ"¶PLQXWHV
after the test block, or have a positive discography; they will be randomised to a group who 
receives a minimal interventional treatment + a multidisciplinary pain programme versus 
patients receiving the multidisciplinary pain programme alone.  
Patients randomised to minimal interventional procedures will be treated according to the 
Guideline low back pain (NVA, NVvN et al. 2011). 
 
Besides these three randomized trials for subgroups of patients, all patients referred to the 
participating pain clinics and who give informed consent will be part of an observational 
study. The observational data will inform us about the proportion of patients with facet joint 
pain, disc pain, SI pain and a combination of these, the proportion of patients with a positive 
block within these four groups, and the clinical outcomes of patients with a negative block. 
 
Main study parameters/endpoints: The primary outcome measure will be measuring pain 
intensity with the NRS, at 3 months after the intervention.  
 
Nature and extent of the burden and risks associated with participation, benefit and 
group relatedness:  
Participating in this trial means that difference in pain and perceived improvement in 
functioning will be measured at 3 and 6 weeks after the intervention; patients have to fill in 
web based questionnaires (see 7.1. for the questionnaires) at baseline, 3, 6, 9, and 12 
months; all are referred to a multidisciplinary pain programme, and they are randomised to 
receive minimal interventional procedures or no additional treatment. The multidisciplinary 
pain program is standard care, which means that patients will not be withheld from standard 
care. 
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1. INTRODUCTION AND RATIONALE 
 
In the Netherlands the majority of patients with low back pain is successfully treated 
in primary care. Approximately 20% of the patients, however, still have symptoms 
after 3 months and 5% after 1 year. In The Netherlands, costs of low back pain are 
HQRUPRXV¼ELOOLRQLQ(Lambeek, van Mechelen et al. 2010). Patients with 
chronic low back pain are responsible for the majority of the high costs. 
Mechanical low back pain is defined as pain resulting from single sources: facet, 
discus, sacroiliac joint or a combination of these. In the proposal we use the 
terminology in this way.  
When primary care treatment has not been successful in alleviating symptoms, 
patients may be referred to medical specialists. Minimal interventional procedures 
are commonly used by anaesthesiologists in a subgroup of patients with mechanical 
low back pain arising from structures like facet joints, discus and sacroiliac joint or 
combinations of these. In The Netherlands there are more than 75 certified pain 
clinics that use these procedures. Indications and treatment algorithms are 
described in the evidence based Guideline low back pain (NVA, NVvN et al. 2011). 
Although these procedures are commonly used, strong evidence for their 
effectiveness is lacking and economic evaluations have not been performed. This 
multidisciplinary clinical guideline has currently been developed with support of the 
Dutch Society of Medical Specialists. 
There is consensus among anaesthesiologists, as reflected by recommendations in 
this guideline, that minimal interventional procedures are effective for patients with 
intervertebral disc, facet joint and sacroiliac joint pain or mixed forms of these. This 
seems to be in contrast with recently performed systematic reviews and 
multidisciplinary international clinical guidelines, which concluded that there is no 
strong evidence that supports the effectiveness of minimal interventional procedures 
in patients with chronic low back pain. The main reason is that randomised 
controlled trials with a low risk of bias and an adequate sample size are lacking. A 
recent systematic review issued by the Dutch Health Insurance Council (CVZ 
26/3/2011) showed that the effectiveness of minimal interventional procedures for 
the total group of chronic low back pain is unclear and the cost-effectiveness 
unknown. Based on this lack of evidence, the Dutch Health Insurance Council (CVZ) 
has decided to advise the Ministry of Health in The Netherlands not to reimburse 
minimal interventional procedures for low back pain within the Dutch public health 
insurance system. The anaesthesiologists claim that they are only treating a 
subgroup of these patients, namely patients with mechanical low back pain. It is 
important for care providers to evaluate the effectiveness and cost-effectiveness of 
minimal interventional procedures in this subgroup of patients. 
Health insurance companies often have contracts with hospitals agreeing to 
reimburse treatment for patients with a specific health problem at specified costs 
without specifying the care that will be delivered. The use of diagnostic and 
therapeutic interventions is at the discretion of the medical specialists. For health 
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insurance companies it is important to know whether the care that is reimbursed is 
effective and cost-effective. 
The aim of his project will be to provide the lacking information. The Dutch 
Association of Anaesthesiologists, the Dutch Spine Society, the Dutch Health 
Insurance Council (CVZ) and the VUmc and Erasmus MC have all explicitly 
acknowledged the importance of this project.  
 
ABR 39578/ ZonMW 17 1202013  Minimal interventional procedures 
 
Version number: 1.4, August 2012  11 of 31 
2. OBJECTIVES 
 
Primary Objective: The main objective of this project is to evaluate the effectiveness 
and cost-effectiveness of minimal interventional procedures as an add-on to a 
multidisciplinary pain programme for patients with chronic mechanical low back pain 
who are referred to a pain programme/pain clinic.  
The primary outcome measure will be measuring pain intensity with the NRS at 3 
months after the intervention. 
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3. STUDY DESIGN 
 
Economic evaluation alongside a clinical study with four subgroups for patients with 
mechanical low back pain who did not respond to conservative primary care and 
were referred to a pain clinic.  
 
 
 
 
 
 
 
 
 
Follow ± up measurements after 3 and 6 weeks: difference in pain and perceived 
improvement. 
Follow up measurements after 3, 6, 9 and 12 months: difference in pain, perceived 
improvement, recovery, pain function, quality of life and patient satisfaction. 
 
An observational study will be done alongside these trials 
 
* Abbreviations: multidisc. pain program: multidisciplinary pain programme; M.I.P.: minimal interventional 
procedures 
 
Referral ro pain clinic of patients with mechanical low back pain
Baseline measurement, clinical evaluation, 
Informed consent
Facet Joint Pain Sacro Iliacal Joint Pain
Combination of SI, Facet and/or 
Disc pain
Randomisation
Diagnostic blockadeDiagnostic blockade
Positive Negative Positive Negative
Randomisation Randomisation
Multidisc. pain 
programme + 
M.I.P
Multidisc. pain 
programme
Multidisc. pain 
programme + 
M.I.P.
Multidisc. pain 
programme
Multidisc. pain 
programme + 
M.I.P.
Multidisc. pain 
programme
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4. STUDY POPULATION 
 
4.1 Population (base) 
Patients are recruited at the departments of Anaesthesiology, i.c. the pain clinics of 
the participating hospitals. In this study all patients who are referred to a pain 
programme/pain clinic with mechanical low back pain will be invited to participate. 
General practitioners and medical specialists who referred patients to the pain 
clinics will be informed about participation of their patients in the study. 
 
4.2 Inclusion criteria 
Chronic (more than 3 months) mechanical low back pain symptoms, age between 
18 and 70 years, no improvement of symptoms after at least three months of 
conservative treatment according to the Dutch guidelines for non-specific low back 
pain (GP care (advise to stay active and pain medication) and exercise therapy) in 
primary care. Patients must report pain on a NRS scale of 6 or higher. 
3DWLHQWVPXVWDQVZHUµ\HV¶RQWKHTXHVWLRQµLVWKHUHDRUPRUHUHGXFWLRQLQ
SDLQ"¶PLQXWHVDIWHUWKHWHVWEORFN, or the disc provocation test must be positive.  
 
4.3 Exclusion criteria 
Patients with severe psychiatric or severe psychological problems, pregnant women, 
and patients who are not able to complete the questionnaires.  
Anticoagulant drug therapy and/or disturbed coagulation BMI > 35. Involved in a 
work related legal dispute and /or liability claim. 
Patients with less than 50% reduction in pain after the test block, or a negative disc 
provocation test. Patients that underwent instrumented surgery in the area to be 
investigated a laminectomy or a spondylodesis. 
 
4.4 Sample size calculation 
Using a power of .9, alpha .05 and a correlation of .5 for repeated measurements, a 
total of 85 patients per group are needed to detect a clinically relevant mean 
difference of 2 points on the Numerical Rating Scale (SD 4). Anticipating potential 
study withdrawal (20%) 102 patients per group or 204 patients per randomized 
comparison are needed. In total we will need to include 612 patients in this study.  
 
The primary outcome measure is the difference in pain intensity, measured with the 
numeric rating scale 3 months after the intervention. Since the intervention is 
directed at pain reduction, it may be expected that the effects of the minimal 
invasive procedures will show after a short period. A long term follow up period of 12 
months is chosen to evaluate whether these effects persist, and also to create a 
time horizon that is long enough for the economic evaluation. 
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Because our primary outcome measure is the pain difference after 3 months, 
repeated measurements are not relevant for the sample size calculation. 
 
The difference of 2 points in the NRS is based on a review by Ostelo et al. (Ostelo, 
Deyo et al. 2008), that found a Minimal Important Change of the NRS of 2 points. 
 
Since these minimal interventional procedures have not been studied before, no SD 
can be found in the literature. This is in fact one of the reasons for these studies. 
7KH6'RIZDVFKRVHQZLWKDQµHGXFDWHGJXHVV¶,WPD\EHDUELWUDU\EXWLQDQ\
case it is conservative, and makes sure that we will include enough patients to find 
clinically relevant effects.  
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5. TREATMENT OF SUBJECTS 
 
5.1 Investigational product/treatment 
The selection of adequate patients in the diagnostic phase, as well as the invasive 
treatment of patients is usual care, as described in the Guideline low back pain 
(NVA, NVvN et al. 2011).  
 
Based on signs and symptoms, patients with suspicion of a single entity, namely 
pain arising from the facet joints or sacroiliac joint will receive a test block with local 
DQDHVWKHWLFV,ISDWLHQWVDQVZHUµ\HV¶ WRWKHTXHVWLRQµLVWKHUHDRUPRUH
UHGXFWLRQLQSDLQ"¶PLQXWHVDIWHUWKHWHVWEORFNSDWLHQWVZLOOEHVFKHGXOHGWR
receive a minimal interventional treatment.  
Patients with suspicion of pain arising from the intervertebral disc will receive as test 
a provocative discography. If this test is positive than they will be scheduled to 
receive a minimal interventional treatment.  
 
The minimal interventional procedures will take place according to a pre-specified 
approach: 
1) Patients with facet joint pain will receive radiofrequency denervation of the first 
ramus dorsalis at L3, L4, L5 and S1. 
2) Patients with intervertebral disc pain will receive a denervation of the involved 
discus. 
3) Patients with sacroiliac joint pain will receive radiofrequency denervation of the 
ramus dorsalis at L5, S1, S2 and S3. 
4) Patients with a combination of the single entities will be randomised after the 
clinical diagnosis to a group who receives minimal interventional treatments (i.e. a 
combination of the interventions mentioned under 1, 2 and 3) and a multidisciplinary 
pain programme.  
 
5.2 Use of co-intervention (if applicable) 
Any co intervention will be measured and included in the cost effectiveness analysis. 
 
5.3 Escape medication (if applicable) 
Not applicable 
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6. INVESTIGATIONAL MEDICINAL PRODUCT 
 
 Not applicable 
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7. METHODS 
 
7.1 Study parameters/endpoints 
7.1.1 Main study parameter/endpoint 
The primary outcome will be measuring pain intensity with the NRS at 3 months 
after the intervention. 
 
7.1.2 Secondary study parameters/endpoints 
NRS = Numeric Rating Scale; EQ-5D = EuroQol; ODI = Oswestry Disability Index; MPI = Multidimensional Pain Inventory; CEQ 
= Credibility/Expectancy Questionnaire; PCI = Pain Coping Inventory; PCL = Pain Cognition List; 4DSQ = Four-Dimensional 
Symptoms Questionnaire; CPAQ = Chronic Pain Acceptance Questionnaire; HADS = Hospital Anxiety Depression Scale 
 
Follow-up will be 12 months. All patients participating in the trial will complete 
questionnaires at baseline and after 3, 6, 9, and 12 months. (The difference in pain 
intensity and the global- perceived improvement in functioning and quality of life will 
also be measured at 3 and 6 weeks after the intervention). We will ask patients to 
complete web-based questionnaires. If patients do not have access to the internet or 
prefer hard copies, we will provide these. Study subjects included in the study will 
receive up to two (e-mail) reminders to fill out the questionnaires. If patients still not 
respond the investigators will try to contact the patients by telephone once. If the 
patient then refuses to fill out the questionnaires the investigators will ask if by 
telephone they can ask the following at the three month measure points: Pain 
Outcome measures                                                                     Follow-up 
 Baseline 3 
weeks 
6 
weeks 
3 
months 
6 
months 
9 
months 
12 
months 
Primary outcomes RCT 
       
Pain Intensity (NRS) x x x x x x x 
 
Secondary outcomes 
       
Global perceived recovery (NRS) x x x x x x x 
Quality of life (EQ-5D) x x x x x x x 
Patient satisfaction (NRS) x   x x x x 
Functional Status (ODI) x   x x x x 
General health (Rand-36) x   x x x x 
Chronic pain experience (MPI) x   x x x x 
        
Others 
       
Demographic data x       
Pain expectation (CEQ) x       
Pain coping strategies (PCI) x       
Pain cognition (PCL) x       
Depression etc. (4DSQ) x       
Pain acceptance (CPAQ) x       
Anxiety, depression (HADS) x       
        
Economic evaluation 
 
Costs (diaries) monthly 
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Intensity (NRS), Global perceived recovery (NRS) and Patient satisfaction (NRS). 
Patients who refuse, will be considered lost to follow up. The core set of primary 
outcomes recommended for low back pain research (Bombardier 2000) will be used: 
global perceived recovery (7-point scale), functional status (Oswestry Disability 
Index (ODI)), and pain intensity (leg and back) (11-point NRS). Also general health 
(Rand-36), quality of life (EuroQol-5D) and patient satisfaction (NRS) are measured. 
The Multidimensional Pain Inventory (MPI) will be used to assess a number of 
dimensions of the chronic pain experience, including pain intensity, emotional 
distress, cognitive and functional adaptation, and social support. Patient expectation 
will be measured at baseline, using the CEQ. Pain cognition and coping will be 
measured with the Pain Cognition List and the Pain Coping Inventory. 
Furthermore, psychological questionnaires will be used at baseline to be able to 
exclude patients with severe psychiatric or psychological complaints: the 4 
Dimensional Symptoms Questionnaire (4DSQ), the Chronic Pain Acceptance 
Questionnaire (CPAQ) and the Hospital Anxiety Depression Scale (HADS). 
Amongst patients that have completed the full year of follow up, dining vouchers will 
be distributed by means of a raffle. 
 
7.1.3 Other study parameters 
Economic evaluation: General considerations 
Four economic evaluations will be performed alongside the four randomized trials. 
The aim of the economic evaluation is to determine and compare the total 
rehabilitation-related costs for patients in both trial arms, and to relate these costs to 
the effects of these two groups. The economic evaluations will be performed 
according to the intention-to-treat principle and from a societal perspective.  
 
Economic evaluation: Costs 
&RVWVLQGLFDWRrs, the following costs are considered in this study: 
- Costs of minimal interventional procedures 
- Costs of the rehabilitation programme 
- Other health care costs including the costs of physiotherapy (during follow up and 
in the control group), manual therapy, additional visits to other health care providers 
(e.g. GPs, medical specialist), prescription of medication, professional home care 
and hospitalisation. 
- Patient and family costs include out-of-pocket expenses (i.e., over the counter 
medication) and costs of paid and unpaid help. 
- Costs due to loss of production due to LBP-related work absenteeism (paid jobs 
and unpaid jobs). 
 
0HDVXUHPHQWRIYROXPHV: 
- Number of treatment sessions during the intervention period will be registered by 
the therapist on standardised forms. 
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- All other health care costs, patient and family costs and costs due to production 
loss will be registered by means of cost questionnaires to be administered by the 
patients (Goossens, Rutten-van Molken et al. 2000). These cost questionnaires 
measure resources consumed on a monthly basis. Patients will receive the first 
questionnaire at baseline; the following diaries at the 3 weeks follow up measure, 
the following at the 6-week follow-up, etc. We will ask patients to complete web-
based cost questionnaires. If patients do not have access to the Internet or prefer 
hard copies, we will provide these.  
6RXUFHVRIFRVWSULFHV 
Costs will be valued using the guidelines published in the updated handbook for 
economic evaluation in the Netherlands (Hakkaart van Roijen, Tan et al. 2010). If 
not available then the real cost prices are calculated through the bottom-up method. 
Visits to other health care professionals (e.g. chiropractor) will be estimated on the 
basis of fees and prices charged by the professional organisation. The costs of 
medication will estimated on the basis of prices charged by the Royal Society for 
Pharmacy. Costs of production losses due to LBP will be estimated for both paid 
and unpaid labour. For paid labour the costs will be calculated using both the human 
capital approach and the friction cost approach (Koopmanschap and Rutten 1996). 
For unpaid labour, the indirect costs will be estimated as the costs of production 
losses due to ongoing or renewed complaints in back and/or leg, e.g. voluntary work 
and household work, using shadow prices.  
 
Imaging 
It is standard care, in performing the minimal interventional treatments as described 
under 5.1, to make and save radiographic images of the needle positions. Images 
saved in the Facet RCT will be submitted to an expert panel to assess correct 
needle placement. Retrospectively we will submit all available (anonymized) images 
taken in the Facet RF RCT to a panel, and have them judged twice, with a 1.5 
month interval. Both timHVZHZLOODVNWKHSDQHOWRMXGJHWKHLPDJHVDVµFRUUHFW¶
µLQFRUUHFW¶RUµXQVXUH¶- needle placement. 
Out of this we want to determine an inter- and  intra- observer reliability. If the 
UHOLDELOLW\LVKLJKZHZLOOGHWHUPLQHZKHWKHUµFRUUHFWSODFHPHQW¶indeed shows a 
higher pain reduction (NRS) after 3 months. 
 
7.2 Randomisation, blinding and treatment allocation 
Central randomisation will be performed by a computer-generated list of random 
numbers. The outcome of the randomisation will be automatically reported to the 
local nurse who entered a positive diagnostic test in the datamanagement system. 
Randomisation will be stratified for clinics. 
 
In this pragmatic trial patients and care providers will not be blinded. Because all 
outcome measures are self-reported, the outcome measurement is also not blinded. 
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Data analysis will be conducted blinded for treatment allocation and blinding will only 
be finished after the final analyses have been concluded.  
To evaluate whether lack of blinding is associated with bias, expectations and 
preferences of patients will be measured before randomisation and after treatment 
allocation and patient satisfaction after treatment and during follow-up.  
 
7.3 Study procedures 
The selection of adequate patients in the diagnostic phase, as well as the invasive 
treatment of patients is usual care, described in the Guideline low back pain (NVA, 
NVvN et al. 2011).  
On entry in the pain clinic every patient will be asked to fill the set of primary and 
secondary outcomes. 
Eligible patients will be informed about the trial and have two weeks time to react. 
Patients will be included when an informed consent has been given.  
Based on signs and symptoms, patients with suspicion on a single entity, namely 
pain arising from the facet joints or sacroiliac joint will receive a test block with local 
DQDHVWKHWLFV,ISDWLHQWVDQVZHUµ\HV¶WRWKHTXHVWLRQµLVWKHUHDRUPRUH
UHGXFWLRQLQSDLQ"¶PLQXWHVDIWHUWKHWHVWEORFNSDWLHQWVDUHrandomized in one of 
the study groups. Patients with the suspicion of pain arising from the intervertebral 
disc will receive a provocative discography.  
Patients with pain suspected to arise from multiple entities, will be randomized prior 
to the test block and provocative discography. The patients will follow an intention to 
treat protocol. 
 
Patients will be randomised to a group who receives a multidisciplinary pain 
programme with a minimal interventional treatment or a group receiving a 
multidisciplinary pain programme alone. 
 
All patients will receive the same standard multidisciplinary pain programme 
according to the guideline of the Royal Dutch Society for Physical Therapy 
(Bekkering, Hendriks et al. 2005). Referral and coordination will take place by the 
anaesthesiologist; a physiotherapist will be involved, and a psychologist if 
necessary. The treatment will focus on activation mobilisation and consist of graded 
activity. 
 
If patients in the non-interventional study groups have not improved or recovered 
after three months, they will not receive interventional procedures but will go back to 
the GP or medical specialist that had referred them to the pain clinic. We will also 
closely monitor and register additional care in this group. 
Apart from the standard set of outcomes for low back pain research, participants in 
the study will fill in an economic evaluation and a monthly cost diary.  
All questionnaires will be repeated at baseline, 3, 6, 9 and 12 months.  
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Besides these four randomized trials for subgroups of patients, all patients referred 
to the participating pain clinics and who give informed consent will be part of an 
observational study. The observational data will inform us about the proportion of 
patients with facet joint pain, disc pain, SI pain and a combination of these, the 
proportion of patients with a positive block within these four groups, and the clinical 
outcomes of patients with a negative block. 
 
Participating in this trial means that difference in pain and perceived improvement in 
functioning will be measured at 3 and 6 weeks after the intervention; patients have 
to fill in web based questionnaires (see 7.1.2. for the questionnaires) at baseline, 3, 
6, 9, and 12 months; all are referred to a multidisciplinary pain programme, and they 
are randomised to receive the minimal interventional procedures or no additional 
treatment.  
 
7.4 Withdrawal of individual subjects 
Subjects can leave the study at any time for any reason if they wish to do so without 
any consequences. The treating physician can decide to withdraw a subject from the 
study for urgent medical reasons. 
 
7.5 Replacement of individual subjects after withdrawal 
Until the sample size for the study has been reached, candidates can participate. 
Patients will not be replaced. No specific conditions apply for replacing an individual 
subject after withdrawal. When a patient withdraws him/herself (or is withdrawn by 
the investigator) he/she can be treated for his/her medical condition outside the 
study. 
 
7.6 Follow-up of subjects withdrawn from treatment 
After withdrawal patients will be asked to keep filling in the questionnaires, and an 
intention to treat analysis will be performed. 
 
7.7 Premature termination of the study 
Premature termination of the study is possible under the following circumstances: 
A) If no positive decision is obtained with regard to the research or if the judgement 
of the competent medical research ethics committee that has assessed the research 
is irrevocably revoked;  
B) In the event that Section 13i, clause 5 of the Medical Research Involving Human 
Subjects Act applies, if the Central Committee or the Minister of Health, Welfare and 
Sport has made an irrevocable objection to the performance of the research with 
medicinal products (only applicable for medicinal products); 
C) If a reasonable case can be made for terminating the research in the interests of 
the subjects' health; 
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D) If it transpires that continuation of the research cannot serve any scientific 
purpose, and this is confirmed by the medical research ethics committee that has 
issued a positive decision on the research; 
E) If one of the two parties has been declared insolvent, or if a petition has been 
filed for liquidation of one of the two parties; 
F) If one of the two parties fails to comply with the obligations arising from the 
agreement and, provided compliance is not permanently impossible, this compliance 
has not taken place within thirty days after the defaulting party has received a 
written request to comply, unless failure to comply is out of reasonable proportion to 
the premature termination of the research. 
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8. SAFETY REPORTING 
 
8.1 Section 10 WMO event 
In accordance to section 10, subsection 1, of the WMO, the investigator will inform 
the subjects and the reviewing accredited METC if anything occurs, on the basis of 
which it appears that the disadvantages of participation may be significantly greater 
than was foreseen in the research proposal. The study will be suspended pending 
further review by the accredited METC, except insofar as suspension would 
MHRSDUGLVHWKHVXEMHFWV¶KHDOWK7KHLQYHVWLJDWRUZLOOWDNHFDUHWKDWDOOVXEMHFWVDUH
kept informed.  
 
8.2 Adverse and serious adverse events 
Adverse events are defined as any undesirable experience occurring to a subject 
during the study, whether or not considered related to [the investigational product / 
the experimental treatment]. All adverse events reported spontaneously by the 
subject or observed by the investigator or his staff will be recorded. 
 
A serious adverse event is any untoward medical occurrence or effect that at any 
dose:  
- results in death; 
- is life threatening (at the time of the event); 
- requires hospitalLVDWLRQRUSURORQJDWLRQRIH[LVWLQJLQSDWLHQWV¶
hospitalisation; 
- results in persistent or significant disability or incapacity; 
- is a congenital anomaly or birth defect; 
- is a new event of the trial likely to affect the safety of the subjects, such as 
an unexpected outcome of an adverse reaction, lack of efficacy of an IMP used 
for the treatment of a life threatening disease, major safety finding from a newly 
completed animal study, etc. 
 
All SAEs will be reported through the web portal ToetsingOnline to the accredited 
METC that approved the protocol, within 15 days after the sponsor has first 
knowledge of the serious adverse reactions. 
SAEs that result in death or are life threatening should be reported expedited. The 
expedited reporting will occur not later than 7 days after the responsible investigator 
has first knowledge of the adverse reaction. This is for a preliminary report with 
another 8 days for completion of the report.  
 
8.2.1 Suspected unexpected serious adverse reactions (SUSAR) 
Not applicable 
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8.2.2 Annual safety report 
Not applicable 
 
8.3 Follow-up of adverse events 
All adverse events will be followed until they have abated, or until a stable situation 
has been reached. Depending on the event, follow up may require additional tests or 
medical procedures as indicated, and/or referral to the general physician or a 
medical specialist. 
 
8.4 Data Safety Monitoring Board (DSMB) 
A data safety monitoring board (DSMB) will not be assembled for this study. All 
adverse events, serious or not, unanticipated or not, will be reported to the 
appropriate ethics and regulatory agencies in accordance with reporting 
requirements. 
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9. STATISTICAL ANALYSIS 
 
9.1 Descriptive statistics 
All patients will be given a distinctive number; data will be analysed anonymously. 
Baseline comparability was performed by descriptive statistics to examine if 
randomisation was successful.  
 
9.2 Univariate analysis 
An intention-to-treat analysis will be conducted for each follow-up moment. Baseline 
data (demographics, pain expectation and the psychological variables) will be 
analysed for comparing the difference between the interventiongroup and the 
controlgroup for each RCT. 95%-confidence intervals will be calculated for the 
difference of percentages (Chi-square distribution) and means (t-distribution) for 
dichotomous and continuous outcome variables, respectively.  
 
9.3 Multivariate analysis 
To compare changes in pain between the interventiongroup and the controlgroup for 
each RCT after three months multilevel analyses will be performed. 
 
In case of unequal distributions of prognostic factors, multivariate analysis 
techniques will be used to correct for these between-group differences in prognosis.  
 
Change scores for the primary and secondary outcomes will be calculated by 
substracting the baseline scores from the post-treatment scores (after 3 and 6 
weeks, 3, 6, 9, and 12 months) and compare those for the intervention and the 
controlgroup using a t-test. 
 
Economic evaluation 
 
For the economic evaluation of each RCT, multivariate analyses will be performed 
as well. Costs and QALYS will be compared for the intervention- and the 
controlgroup (with costs/QALYS as dependent variable and group as independent 
variable) 
 
Cost-effectiveness and a cost-utility analysis will be performed. Cost-effectiveness 
ratios will be calculated by dividing the difference between the mean costs of the two 
treatment groups by the difference in the mean effects of the two treatment groups. 
5DWLR¶VZLOOLQFOXGHWKHFOLQLFDOHIIHFWPHDVXUHVRIWKHWULDOLHJHQHUDOSHUFHLYHG
recovery, functional status, pain intensity. Cost-utility will be based on the EuroQol 
and expressed in costs per QALY. Cost-effectiveness and cost-utility ratios will be 
estimated using bootstrapping techniques and acceptability curves and net 
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monetary benefit will also be estimated. Sensitivity analysis on the most important 
cost drivers will be performed in order to assess the robustness of the results. 
 
 
- Patient outcome analysis 
The primary effect measures will also be used in the economic evaluation: 
1) general improvement, 2) functional status, 3) pain intensity, and 4) work 
absenteeism. Utilities will be measures using the EuroQol-5D. Overall utility scores 
for population-based quality of life can be obtained and will be expressed as 
4$/<¶V4$/<¶VZLOOEHFDOFXODWHGE\PXltiplying the utility of a health state by the 
time spent in this health state using the Dutch valuation tariff (Lamers, Stalmeier et 
al. 2005). 
 
9.4 Interim analysis 
Not applicable 
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10. ETHICAL CONSIDERATIONS 
 
10.1 Regulation statement 
The study will be conducted according to the principles of the Declaration of Helsinki 
(WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI - Ethical 
Principles for Medical Research Involving Human Subjects; Adopted by the 18th 
WMA General Assembly, Helsinki, Finland, June 1964, and amended by the: 29th 
WMA General Assembly, Tokyo, Japan, October 1975, 35th WMA General 
Assembly, Venice, Italy, October 1983, 41st WMA General Assembly, Hong Kong, 
September 1989, 48th WMA General Assembly, Somerset West, Republic of South 
Africa, October 1996, 52nd WMA General Assembly, Edinburgh, Scotland, October 
2000, 53rd WMA General Assembly, Washington 2002 (Note of Clarification on 
paragraph 29 added), 55th WMA General Assembly, Tokyo 2004 (Note of 
Clarification on Paragraph 30 added) and 59th WMA General Assembly, Seoul, 
October 2008) and in accordance with the Medical Research Involving Human 
Subjects Act (WMO). 
 
10.2 Recruitment and consent 
Patients are recruited at the departments of Anaesthesiology, i.c. the pain clinics of 
the participating hospitals. In this pragmatic trial, all patients who are referred to a 
pain programme/pain clinic with mechanical low back pain will be invited to 
participate. General practitioners and medical specialists who referred patients to 
the pain clinics will be informed about participation of their patients in the study. 
Patients who meet the criteria are informed of the purpose and procedures of the 
study; each patient receives a general brochure concerning scientific research 
involving human subjects (in Dutch: medisch-wetenschappelijk onderzoek met 
mensen) and a patient information letter (section E1 of the protocol). After giving 
informed consent by means of an informed consent patients are enrolled in the 
study. 
 
10.3 Objection by minors or incapacitated subjects (if applicable) 
Not applicable 
 
10.4 Benefits and risks assessment, group relatedness 
Minimal interventional procedures provide alternatives for patients with mechanical 
back pain who did not improve on primary care treatment. No major complications 
have been reported on these procedures.  
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10.5 Compensation for injury 
The sponsor/investigator has a liability insurance which is in accordance with article 
7, subsection 6 of the WMO. 
The sponsor (also) has an insurance which is in accordance with the legal 
requirements in the Netherlands (Article 7 WMO and the Measure regarding 
Compulsory Insurance for Clinical Research in Humans of 23th June 2003). This 
insurance provides cover for damage to research subjects through injury or death 
caused by the study. 
 
1. ¼-- (i.e. four hundred and fifty thousand Euro) for death or injury for 
each subject who participates in the Research; 
2. ¼-- (i.e. three million five hundred thousand Euro) for death or injury 
for all subjects who participate in the Research;  
3. ¼-- (i.e. five million Euro) for the total damage incurred by the 
organisation for all damage disclosed by scientific research for the Sponsor as 
µYHUULFKWHU¶LQWKHPHDQLQJRIVDLG$FWLQHDFK\HDURILQVXUDQFHFRYHUDJH 
The insurance applies to the damage that becomes apparent during the study or 
within 4 years after the end of the study. 
 
10.6 Incentives (if applicable) 
Not applicable 
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11. ADMINISTRATIVE ASPECTS AND PUBLICATION 
 
11.1 Handling and storage of data and documents 
Web based questionnaires will be used to assess questionnaires, and an online 
data management system will be used for the management of these questionnaires. 
This software is installed on the computers of the Erasmus MC MGZ and VU 
University EMGO department, so that backup and access protection have been 
arranged. 
The patients will receive an email notification when a questionnaire is due. The 
database itself is safeguarded with tokens and passwords. The trial coordinator of 
the Erasmus MC controls the patient tracking programme that enables her to send 
out emails, and check whether all questionnaires have been completed. Only the 
research coordinators of the VUmc and the Erasmus MC have access to all data. If 
the patients do not have access to the internet or prefer hard copies, we will provide 
these. The data from measurements and questionnaires will be stored in the 
Promise database.  
The researchers at the VUmc and the Erasmus MC will only receive the data, and 
these will be processed without knowing the treatment group. The coding and 
randomisation will take place using a computer based list, safeguarded by the 
statistician of the Center for Pain Medicine of the Erasmus MC. The patient records 
will be coded by a code for the center that included the patient, and a number, 
starting with 1 for the first patient.  
 
11.2 Amendments  
Amendments are changes made to the research after a favourable opinion by the 
accredited METC has been given. All amendments will be notified to the METC that 
gave a favourable opinion.  
All substantial amendments will be notified to the METC and to the competent 
authority. 
Non-substantial amendments will not be notified to the accredited METC and the 
competent authority, but will be recorded and filed by the sponsor.  
 
11.3 Annual progress report 
The sponsor/investigator will submit a summary of the progress of the trial to the 
accredited METC once a year. Information will be provided on the date of inclusion 
of the first subject, numbers of subjects included and numbers of subjects that have 
completed the trial, serious adverse events/ serious adverse reactions, other 
problems, and amendments.  
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11.4 End of study report 
The investigator will notify the accredited METC of the end of the study within a 
period of 8 weeks. The end of the study is defined as the laVWSDWLHQW¶VODVWYLVLW 
In case the study is ended prematurely, the investigator will notify the accredited 
METC, including the reasons for the premature termination. 
Within one year after the end of the study, the investigator/sponsor will submit a final 
study report with the results of the study, including any publications/abstracts of the 
study, to the accredited METC.  
 
 
11.5 Public disclosure and publication policy 
The principal investigator is free to publish. 
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eAppendix. Description radiofrequency denervation intervention. 
 
Radiofrequency denervation of the facet joints:  
A C-arm image intensifier was positioned in a slightly (10±15°) oblique position, with 
the patient in prone position. A 22 G SMK needle with a 10-mm active curved tip was 
introduced at each entry point. The position of the cannula was checked on the lateral and 
AP projection. The depth was adjusted until the tip of the cannula was at the level of a 
line connecting the posterior aspects of the intervertebral foramen. Sensory stimulation 
(50Hz) was positive when the patient felt paresthesia, and motor stimulation (2Hz) was 
positive with visible muscle stimulation but no leg contractions. Once the position of the 
electrode was satisfactory, 1-2 ml per level ml 2% lidocaine was injected and a 90°C 90 
seconds RF lesion was made of the medial ramus dorsalis of L3-4, L4-5, and L5-S1. 
 Radiofrequency denervation of the sacroiliac joints:  
The choice of technique for radiofrequency denervation was left to the discretion of the 
physician. Participants received either the Cooled RF technique (SInergy, Kimberly Clark 
Health Care, Roswell GA, USA); Bipolar Palisade Technique; or SIMPLICITY III Probe 
technique (Neurotherm, St Paul MN, USA). 
For the Cooled RF technique1: Under fluoroscopy, 25G needles were placed along the 
lateral wall of each foramen, with the tip at the opening. An Epsilon® ruler was used 
together with the reference needles as landmarks for the lesions. Using the introducer, 
stylet and probe provided by the manufacturer, radiofrequency lesions were made (at 
© 2017 American Medical Association. All rights reserved. 
02:30, 04:00 and 05:30 for S1 and S2 and 02:30, 04:00 for S3 on the right side, inversely 
on the left) at a temperature of 60°C for 2.5 minutes per lesion.  
The Palisade Technique2: was carried out by drawing a cranial-caudal line between the 
lateral aspect of the sacral foramina and the sacroiliac joint line. Under lateral 
fluoroscopic view six 20G needles with 10mm active tips were placed parallel to each 
other 10mm apart and perpendicular to the sacrum. Stimulations to 2.0V were done to be 
sure there was no motor response. Then eight lesions (90°C, 180 seconds per lesion) were 
made using adjacent parings of the cannulas. The maximum allowed temperature drop 
between cannulas was 30°C. 
The SIMPLICITY III probe3: was inserted at the lateral, inferior border of the sacrum, 
10mm below the S4 foramen under fluoroscopic view. The electrode probe was advanced 
in a cephalad direction along the sacrum, lateral of the foramina, medial to the sacroiliac 
joint and ventral to the ileum. The correct position of the electrodes was checked and the 
RF lesion (85°C for 90 seconds per step) was made. 
In all three techniques RF lesion of the ramus dorsalis of L5/S1 was carried out 
monopolar.4 All lesion sites were anesthetized using 2% lidocaine. 
 Radiofrequency denervation in the combination trial: 
As opposed to the other two trials, participants of the combination trial were randomized 
before a diagnostic block was done. Patients were only treated with a radiofrequency 
denervation when randomized to the intervention group and a positive diagnostic block of 
the facet joint or sacroiliac joint, or a positive provocative discography.5 If none of the 
diagnostic tests were positive, the participant would receive the standardized exercise 
© 2017 American Medical Association. All rights reserved. 
program only. The facet joint and sacroiliac joint radiofrequency denervation were 
performed as described above. The treatment of the intervertebral disc could be done by 
one of two radiofrequency denervation techniques: Intradiscal Electrothermal Therapy or 
Biacuplasty.  
Intradiscal Electrothermal Therapy: Using fluoroscopic control, with the patient prone on 
the operating table, a needle was passed into the injured disc via the side. With the needle 
placed alongside the internal aspect of the posterior annulus, the catheter containing the 
heating coil was manipulated inside the disc. The temperature inside the disc was raised 
to 90°C in 12 minutes, and maintained at 90°C for another four minutes. 
Biacuplasty: Two internally cooled 17 G needles were inserted at the level of the annulus 
fibrosis. Two RF currents were inserted to generate a bipolar configuration. The ideal 
temperature profile is 55/60°C in the inner posterior disc decreasing to 45°C for 12 to 16 
minutes in the peripheral edge of the posterior disc.  
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eTable 1. Baseline Characteristics of Completers vs Non-completers 
Characteristics* Intervention 
Randomized: 
N=125 
Complete 
baseline: 
N=117 
Intervention 
Complete 
N=78 
Complete 
baseline: 
N=78 
Intervention 
Incomplete 
N=47 
Complete 
baseline: 
N=39 
Control 
Randomized: 
N=126 
Complete 
baseline: 
N=116 
Control 
Complete 
N=88 
Complete 
baseline: 
N=88 
Control 
Incomplete 
N=38 
Complete 
baseline: N=28 
FACET JOINT TRIAL 
Age in years (SD) 52.98 (11.48) 54.45 (10.90) 50.10 (12.01) 52.60 (10.79) 53.20 (10.48) 50.71 (11.79) 
Female (N (%)) 65 (55.56%) 45 (57.69%) 19 (48.71%) 60 (51.72%) 48 (54.54%) 16 (57.14%) 
BMI (SD) 26.77 (5.17) 27.23 (5.70) 25.85 (3.76) 27.62 (4.27) 27.94 (4.32) 26.62 (4.07) 
Smoker (N (%)) 34 (29.05 %) 16 (20.51%) 18 (46.15%) 34 (29.05%) 22 (25.00%) 12 (42.85%) 
Education§       
Low (N (%)) 57 (48.72%) 40 (51.28%) 18 (48.61%) 64 (55.17 %) 48 (54.54%) 17 (60.71%) 
Moderate (N (%)) 35 (29.99%) 22 (28.21%) 13 (33.33%) 34 (29.31%) 27 (30.68%) 8 (28.57%) 
High (N (%)) 21 (17.95%) 16 (20.51%) 6 (15.38%) 16 (13.79 %) 13 (14.77%) 3 (10.71%) 
History of back pain 
complaints 
      
Time since first experience 
with low back pain in months 
(median (IQR)) 
146.00 
(49.75-267.67) 
158.17 
(42.29 ± 
304.17) 
146.00 
(54.73-
220.00) 
100.33 
(36.5-186.30) 
115.58 
(36.50-
186.30) 
83.75 
(49.73 ± 
220.63) 
Time since current episode 
with low back pain in months 
(median (IQR)) 
31.33 
(12.17-103.42) 
29.33 
(12.17 ± 83.58) 
36.50 
(8.33-130.63) 
26.73 
(10.54-73.00) 
30.33 
(12.17 ± 
77.57) 
19.75 
(7.25-70.20) 
Married or living with a 
partner (N (%)) 
93 
(79.49%) 
68 
(87.17%) 
25 
(64.10%) 
98 
(84.48%) 
76 
(86.36%) 
22 
(78.57%) 
Expectations (CEQ) a       
Credibility (0-27) 21.36 (3.92) 21.84 (3.38) 20.36 (4.76) 19.47 (5.49) 19.19 (5.87) 20.32 (4.08) 
Expectancy (0-27) 18.97 (4.59) 19.35 (4.35) 18.18 (5.02) 17.36 (5.20) 16.85 (5.62) 18.96 (3.16) 
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Characteristics* Intervention 
Randomized: 
N=125 
Complete 
baseline: 
N=117 
Intervention 
Complete 
N=78 
Complete 
baseline: 
N=78 
Intervention 
Incomplete 
N=47 
Complete 
baseline: 
N=39 
Control 
Randomized: 
N=126 
Complete 
baseline: 
N=116 
Control 
Complete 
N=88 
Complete 
baseline: 
N=88 
Control 
Incomplete 
N=38 
Complete 
baseline: N=28 
Mean (SD) Pain intensity in 
the past week 
(NRS 0-10) b 
7.14 (1.38) 6.99 (1.48) 7.44 (1.11) 7. 19 (1.29) 7.14 (1.27) 7.36 (1.39) 
Mean (SD) Functioning 
(ODI 0-100) c 
35.07 (14.66) 35.02 (14.02) 35.18 (16.07) 34.39 (12.24) 33.88 (11.52) 36.00 (14.36) 
Mean (SD) Quality of life 
(EQ-5D 0-1) d 
0.52 (0.26) 0.55 (0.24) 0.46 (0.29) 0.54 (0.26) 0.55 (0.26) 0.52 (0.25) 
SACROILIAC JOINT TRIAL 
Age in years (SD) 51.58 (10.94)   51.13 (12.22)   
Female (N (%)) 87 (74.35%)   79 (75.96%)   
BMI (SD) 26.73 (4.17)   26.76 (4.53)   
Smoker (N (%)) 29 (26.61%)   31 (29.81%)   
Education§       
Low (N (%)) 59 (54.13%)   53 (50.96%)   
Moderate (N (%)) 32 (29.36%)   32 (30.76%)   
High (N (%)) 18 (16.51%)   18 (17.31%)   
History of back pain 
complaints 
      
Time since first experience 
with low back pain in months 
(median (IQR)) 
97.33 
(37.51-228.12) 
 
- 
 
-
 
65.08 
(27.08-144.21) 
 
-
 
 
-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Characteristics* Intervention 
Randomized: 
N=125 
Complete 
baseline: 
N=117 
Intervention 
Complete 
N=78 
Complete 
baseline: 
N=78 
Intervention 
Incomplete 
N=47 
Complete 
baseline: 
N=39 
Control 
Randomized: 
N=126 
Complete 
baseline: 
N=116 
Control 
Complete 
N=88 
Complete 
baseline: 
N=88 
Control 
Incomplete 
N=38 
Complete 
baseline: N=28 
Time since current episode 
with low back pain in months 
(median (IQR)) 
30.33 
(12.17 ± 76.03) 
 
- 
 
-
 
24.33 
(12.17 ± 66.58) 
 
- 
 
- 
Married or living with a 
partner (N (%)) 
85 (79.61%) 64 (84.21%) 21 (67.74%) 82 (79.61%) 49 (85.96%) 33 (78.57%) 
Expectations (CEQ) a       
Credibility (0-27) 21.36 (4.51) 21.18 (4.51) 21.77 (4.56) 19.88 (5.31) 20.05 (5.60) 19.64 (4.94) 
Expectancy (0-27) 18.75 (4.99) 18.86 (4.82) 18.48 (5.47) 18.23 (5.31) 18.51 (5.09) 17.88 (5.64) 
Mean (SD) Pain intensity in 
the past week (NRS 0-10) b 
7.17 (1.65) 7.09 (1.78) 7.34 (1.310) 7.06 (1.43) 7.12 (1.68) 6.98 (1.035) 
Mean (SD) Functioning 
(ODI 0-100) c 
38.07 (14.07) 38.26 (14.97) 37.63 (11.81) 33.70 (14.43) 34.46 (14.23) 32.70 (14.79) 
Mean (SD) Quality of life 
(EQ-5D 0-1) d 
0.50 (0.27) 0.50 (0.28) 0.47 (0.26) 0.56 (0.27) 0.54 (0.27) 0.60 (0.26) 
COMBINATION TRIAL 
Age in years (SD) 50.80 (11.33)      
Female N (%) 64 (65.31%)      
BMI (SD) 26.84 (3.82)      
Smoker N (%) 23 (23.46%)      
Education§       
Low N (%) 52 (53.06%)      
Moderate N (%) 33 (33.67%)      
High N (%) 12 (12.24%)     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Characteristics* Intervention 
Randomized: 
N=125 
Complete 
baseline: 
N=117 
Intervention 
Complete 
N=78 
Complete 
baseline: 
N=78 
Intervention 
Incomplete 
N=47 
Complete 
baseline: 
N=39 
Control 
Randomized: 
N=126 
Complete 
baseline: 
N=116 
Control 
Complete 
N=88 
Complete 
baseline: 
N=88 
Control 
Incomplete 
N=38 
Complete 
baseline: N=28 
History of back pain 
complaints 
      
Time since first experience 
with low back pain in months 
median (IQR) 
120.58 
(37.32 ± 
222.04) 
 
-
 
 
-
 
 
±
 
 
±
 
 
±
 
Time since current episode 
with low back pain in months 
median (IQR) 
36.50 
(12.17-121.67) 
 
- 
 
-
 
 
± 
 
- 
 
- 
Married or living with a 
partner N (%) 
66 (67.35%) 43 (71.67%) 23 (60.53%) 68 (76.40%) 36 (78.26%) 32 (74.42%) 
Expectations (CEQ) a       
Credibility (0-27) 20.10 (4.70) 20.45 (4.10) 19.54 (5.55) 17.07 (5.99) 16.33 (5.95) 17.90 (5.99) 
Expectancy (0-27) 16.88 (5.78) 17.57 (5.85) 15.75 (5.55) 14.38 (6.24) 13.38 (6.42) 15.50 (5.92) 
Mean (SD) Pain intensity in 
the past week (NRS 0-10) b 
7.19 (1.43) 7.30 (1.28) 7.03 (1.65) 7.43 (1.41) 4.47 (1.25) 7.39 (1.58) 
Mean (SD) Functioning 
(ODI 0-100) c 
39.06 (14.03) 38.00 (13.12) 40.74 (15.38) 37.20 (13.74) 37.16 (15.57) 37.25 (11.54) 
Mean (SD) Quality of life 
(EQ-5D 0-1) d 
0.49 (0.28) 0.50 (0.28) 0.47 (0.28) 0.52 (0.28) 0.54 (0.28) 0.49 (0.29) 
Abbreviations: SD, Standard Deviation; N, number; BMI, Body Mass Index; IQR, interquartile range; CEQ, credibility expectancy 
questionnaire; NRS, Numeric Rating Scale, ODI: Oswestry Disability Index; EQ-5D, EuroQol-5D 
§ Low= pre-school, primary school, lower secondary school; moderate= higher secondary school, undergraduate; high=tertiary, 
university, or postgraduate  
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a
 A higher score indicates more credibility in the effectiveness of the treatment, or higher expectations about the treatment  b A higher 
score indicates more severe pain intensity   c A higher score indicates worse functioning  d A higher score indicates better quality of 
life 
© 2017 American Medical Association. All rights reserved. 
eTable2. Treatment Effects for Secondary Outcomes Based on Intention-to-Treat 
Analyses 
Facet Joint Trial Mean Intervention 
group (95%CI) 
N=125 
Mean Control 
group (95%CI) 
N=126 
Mean difference 
(95%CI) 
P 
value 
EQ5D Utilities***     
  Overall effect     0.01 (-0.03 to 0.04) 0.75 
  Baseline (SD) 0.52 (0.47 to 0.57) 0.54 (0.49 to 0.59)     
  3 weeks 0.69 (0.64 to 0.73) 0.64 (0.59 to 0.68) 0.05 (-0.01 to 0.10) 0.08 
  6 weeks 0.69 (0.66 to 0.73) 0.67 (0.63 to 0.70) 0.03 (-0.03 to 0.08) 0.32 
  3 months 0.68 (0.64 to 0.73) 0.69 (0.65 to 0.73) -0.01 (-0.06 to 0.05) 0.85 
  6 months 0.73 (0.70 to 0.77) 0.71 (0.67 to 0.76) 0.02 (-0.03 to 0.07) 0.42 
  9 months 0.72 (0.68 to 0.76) 0.75 (0.71 to 0.78) -0.05 (-0.10 to 0.01) 0.11 
  12months 0.73 (0.69 to 0.73) 0.73 (0.69 to 0.77) -0.03 (-0.08 to 0.03) 0.37 
Patient satisfaction**     
  Overall effect     -0.01 (-0.30 to 0.28) 0.96 
  3 months 2.95(2.70 to 3.20) 3.26 (3.00 to 3.52) -0.18 (-0.54 to 0.18) 0.34 
  6 months 2.96 (2.74 to 3.17) 3.06 (2.81 to 3.31) 0.01 (-0.35 to 0.38) 0.94 
© 2017 American Medical Association. All rights reserved. 
  9 months 2.88 (2.63 to 3.12) 3.13 (2.83 to 3.42) -0.02 (-0.39 to 0.35) 0.91 
  12 months 2.88 (2.60 to 3.16) 3.01 (2.73 to 3.29) 0.19 (-0.19 to 0.56) 0.32 
MPI Pain severity**         
  Overall effect     0.05 (-0.21 to 0.32) 0.7 
  Baseline 3.87 (3.68 to 4.06) 3.85 (3.70 to 4.00)     
  3 months 2.96 (2.71 to 3.21) 3.20 (2.96 to 3.44) -0.15 (-0.48 to 0.18) 0.36 
  6 months 2.73 (2.48 to 2.98) 2.84 (2.58 to 3.11) -0.03 (-0.37 to 0.31) 0.86 
  9 months 2.73 (2.45 to 3.02) 2.68 (2.40 to 2.97) 0.16 (-0.18 to 0.50) 0.36 
  12 months 2.65 (2.34 to 2.95) 2.58 (2.30 to 2.85) 0.27 (-0.07 to 0.61) 0.12 
MPI interference**         
  Overall effect     -0.06 (-0.31 to 0.19) 0.63 
  Baseline 3.30 (3.07 to 3.52) 3.12 (2.91 to 3.34)     
 3 months 2.62 (2.37 to 2.87) 2.74 (2.48 to 2.99) -0.15 (-0.44 to 0.14) 0.32 
  6 months 2.59 (2.33 to 2.85) 2.57 2.31 to 2.84) -0.02 (-0.31 to 0.27) 0.88 
  9 months 2.38 (2.08 to 2.67) 2.43 (2.14 to 2.72) -0.06 (-0.36 to 0.24) 0.70 
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  12 months 2.40 (2.10 to 2.70) 2.42 (2.12 to 2.71) -0.01 (-0.31 to 0.29) 0.93 
MPI Life control**         
  Overall effect     0.00 (-0.20 to 0.20) 0.98 
  Baseline 3.92 (3.72 to 4.12) 4.18 (4.02 to 4.34)     
  3 months 4.26 (4.06 to 4.45) 4.17 (3.99 to 4.35) 0.17 (-0.08 to 0.41) 0.18 
  6 months 4.13 (3.91 to 4.34) 4.32 (4.13 to 4.52) -0.15 (-0.41 to 0.10) 0.23 
  9 months 4.26 (4.05 to 4.46) 4.31 (4.11 to 4.51) -0.00 (-0.25 to 0.25) 0.99 
  12 months 4.28 (4.07 to 4.48) 4.32 (4.11 to 4.54) -0.02 (-0.28 to 0.23) 0.86 
MPI Affective 
distress** 
        
  Overall effect     0.03 (-0.10 to 0.16) 0.69 
  Baseline 2.71 (2.56 to 2.86) 2.60 (2.46 to 2.73)     
  3 months 2.56 (2.43 to 2.69) 2.46 (2.33 to 2.60) 0.07 (-0.11 to 0.24) 0.46 
  6 months 2.55 (2.41 to 2.69) 2.52 (2.38 to 2.67) -0.03 (-0.20 to 0.15) 0.78 
  9 months 2.49 (2.34 to 2.63) 2.43 (2.29 to 2.56) 0.06 (-0.12 to 0.24) 0.51 
  12 months 2.47 (2.34 to 2.61) 2.48 (2.35 to 2.60) -0.00 (-0.19 to 0.18) 0.97 
MPI Support**         
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  Overall effect     0.06 (-0.14 to 0.26) 0.56 
  Baseline 4.60 (4.41 to 4.80) 4.42 (4.20 to 4.64)     
  3 months 4.43 (4.22 to 4.64) 4.35 (4.10 to 4.60) -0.03 (-0.29 to 0.24) 0.85 
  6 months 4.34 (4.09 to 4.58) 4.22 (3.95 to 4.51) 0.02 (-0.25 to 0.29) 0.88 
  9 months 4.36 (4.10 to 4.63) 4.17 (3.89 to 4.45) 0.12 (-0.15 to 0.39) 0.38 
  12 months 4.37 (4.12 to 4.62) 4.15 (3.83 to 4.46) 0.15 (-0.13 to 0.42) 0.3 
RAND-36 Physical 
health*** 
        
  Overall effect     -0.42 (-4.11 to 3.26) 0.82 
Baseline 46.20 (42.68 to 
49.71) 
47.20 (44.09 to 
50.30)) 
    
  3 months 57.67 (53.80 to 
61.54) 
53.79 (49.91 to 
57.67) 
3.41 (-0.89 to 7.71) 0.12 
  6 months 57.68 (53.80 to 
61.56) 
56.85 (52.99 to 
60.71) 
0.21 (-4.15 to 4.56) 0.93 
  9 months 56.89 (52.68 to 
60.09) 
58.70 (54.93 to 
62.47) 
-2.07 (-6.47 to 2.32) 0.35 
  12 months 57.30 (52.79 to 
61.82) 
58.87 (54.88 to 
62.86) 
-4.02 (-8.45 to 0.40) 0.07 
RAND-36 mental 
health*** 
        
  Overall effect     -0.69 (-3.35 to 1.96) 0.61 
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  Baseline 73.68 (70.85 to 
76.50) 
75.24 (72.52 to 
77.97) 
    
  3 months 75.42 (72.27 to 
78.58) 
75.96 (73.01 to 
78.92) 
-0.66 (-3.91 to 2.60) 0.69 
  6 months 77.36 (74.28 to 
80.43) 
77.46 (74.46 to 
80.46) 
-0.18 (-3.49 to 3.14) 0.92 
  9 months 76.75 (73.51 to 
80.00) 
77.15 (74.00 to 
80.30) 
-1.68 (-5.03 to 1.67) 0.33 
  12 months 77.98 (74.84 to 
81.12) 
76.84 (73.79 to 
80.09) 
-0.26 (-3.64 to 3.13) 0.88 
SACROILIAC 
JOINT TRIAL 
Mean Intervention 
group (95%CI) 
N=116 
Mean Control 
group (95%CI) 
N=112 
Mean difference 
(95%CI) 
P-
value 
EQ5D Utilities***     
  Overall effect     0.02 (-0.02 to 0.06) 0.27 
  Baseline 0.50 (0.44 to 0.55) 0.56 (0.51 to 0.62)     
  3 weeks 0.73 (0.69 to 0.76) 0.62 (0.57 to 0.68) 0.10 (0.03 to 0.16) 0.002 
  6 weeks 0.69 (0.64 to 0.73) 0.66 (0.61 to 0.71) 0.04 (-0.02 to 0.09) 0.22 
  3 months 0.68 (0.64 to 0.73) 0.66 (0.60 to 0.71) 0.05 (-0.01 to 0.11) 0.11 
  6 months 0.74 (0.70 to 0.78) 0.73 (0.69 to 0.78) 0.001 (-0.06 to 0.06) 0.98 
  9 months 0.68 (0.63 to 0.73) 0.73 (0.69 to 0.78) -0.05 (-0.11 to 0.02) 0.15 
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  12months 0.70 (0.65 to 0.74) 0.73 (0.68 to 0.78) -0.02 (-0.09 to 0.04) 0.52 
NRS patient 
satisfaction** 
        
  Overall effect     -0.21 (-0.54 to 0.13) 0.23 
  3 months 2.94 (2.67 to 3.20) 3.42 (3.09 to 3.75) -0.54 (-0.96 to -0.13) 0.01 
  6 months 2.86 (2.59 to 3.13) 2.97 (2.66 to 3.27) -0.05 (-0.46 to 0.37) 0.83 
  9 months 3.05 (2.75 to 3.35) 3.14 (2.79 to 3.49) -0.06 (-0.49 to 0.36) 0.78 
  12 months 3.03 (2.74 to 3.32) 3.25 (2.92 to 3.59) -0.16 (-0.59 to 0.26) 0.45 
MPI Pain severity**         
  Overall effect     -0.06 (-0.38 to 0.25) 0.70 
  Baseline 3.99 (3.80 to 4.18) 3.76 (3.54 to 3.98)     
  3 months 2.90 (2.61 to 3.18) 3.17 (2.85 to 3.48) -0.42 (-0.46 to -0.38) <0.000
1 
  6 months 2.71 (2.43 to 2.99) 2.74 (2.42 to 3.06) -0.07 (-0.46 to 0.33) 0.73 
  9 months 3.01 (2.74 to 3.28) 2.76 (2.43 to 3.08) 0.18 (-0.23 to 0.59) 0.39 
  12 months 2.87 (2.57 to 3.15) 2.71 (2.37 to 3.05) 0.13 (-0.29 to 0.54) 0.54 
MPI interference**         
  Overall effect     -0.04 (-0.31 to 0.23) 0.77 
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  Baseline 3.60 (3.37 to 3.84) 3.32 (3.05 to 3.57)     
  3 months 3.19 (2.95 to 3.44) 2.96 (2.67 to 3.25) -0.10 (-0.43 to 0.24) 0.57 
  6 months 2.86 (2.60 to 3.13) 2.83 (2.50 to 3.13) -0.09 (-0.43 to 0.24) 0.59 
  9 months 2.85 (2.56 to 3.15) 2.68 (2.35 to 3.02) -0.02 (-0.37 to 0.32) 0.89 
  12 months 2.92 (2.62 to 3.22) 2.69 (2.37 to 3.01) 0.10 (-0.25 to 0.45) 0.59 
MPI Life control**     
  Overall effect     0.07 (-0.12 to 0.27) 0.47 
  Baseline 4.11 (3.91 to 4.31) 4.22 (4.04 to 4.40)     
  3 months 4.32 (4.12 to 4.53) 4.23 (3.99 to 4.46) 0.22 (-0.03 to 0.48) 0.08 
  6 months 4.42 (4.24 to 4.60) 4.35 (4.14 to 4.57) 0.04 (-0.21 to 0.30) 0.74 
  9 months 4.28 (4.07 to 4.50) 4.40 (4.14 to 4.66) -0.06 (-0.32 to 0.20) 0.65 
  12 months 4.39 (4.17 to 4.60) 4.37 (4.09 to 4.65) 0.06 (-0.21 to 0.32) 0.66 
MPI Affective 
distress** 
        
  Overall effect     0.07 (-0.07 to 0.20) 0.32 
  Baseline 2.75 (2.59 to 2.91) 2.66 (2.50 to 2.82)     
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  3 months 2.54 (2.39 to 2.68) 2.44 (2.28 to 2.59) 0.08 (-0.12 to 0.27) 0.44 
  6 months 2.54 (2.42 to 2.73) 2.58 (2.42 to 2.73) -0.03 (-0.22 to 0.17) 0.79 
  9 months 2.62 (2.45 to 2.80) 2.44 (2.29 to 2.59) 0.19 (-0.01 to 0.39) 0.07 
  12 months 2.45 (2.30 to 2.60) 2.41 (2.25 to 2.56) 0.05 (-0.15 to 0.25) 0.62 
MPI Support**         
  Overall effect     -0.00 (-0.25 to 0.24) 0.99 
  Baseline 4.95 (4.67 to 5.23) 4.89 (4.64 to 5.13)     
  3 months 4.88 (4.60 to 5.16) 4.69 (4.37 to 5.01) 0.01 (-0.31 to 0.33) 0.97 
  6 months 4.74 (4.44 to 5.03) 4.83 (4.51 to 5.14) -0.09 (-0.42 to 0.24) 0.59 
 9 months 4.83 (4.51 to 5.15) 4.76 (4.44 to 5.07) -0.00 (-0.34 to 0.33) 0.98 
  12 months 4.74 (4.42 to 5.06) 4.79 (4.43 to 5.16) 0.10 (-0.24 to 0.44) 0.57 
RAND-36 Physical 
health*** 
        
  Overall effect     -1.22 (-5.19 to 2.75) 0.55 
  Baseline 45.50 (42.14 to 
48.87) 
48.50 (44.60 to 
52.40) 
    
  3 months 53.91 (50.09 to 
57.73) 
54.37 (49.76 to 
58.98) 
2.21 (-2.82 to 7.24) 0.39 
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  6 months 57.04 (52.98 to 
51.10) 
59.48 (55.21 to 
63.76) 
-1.80 (-6.88 to 3.27) 0.49 
  9 months 55.30 (51.10 to 
59.50) 
60.52 (56.16 to 
64.88) 
-4.35 (-9.54 to 0.85) 0.10 
  12 months 56.98 (52.50 to 
61.46) 
59.80 (55.25 to 
64.34) 
-1.48 (-6.73 to 3.77) 0.58 
RAND-36 mental 
health*** 
        
  Overall effect     0.038 (-175 to 1.82) 0.97 
  Baseline 76.40 (73.53 to 
79.28) 
76.76 (73.99 to 
79.53) 
    
  3 months 76.87 (73.89 to 
79.86) 
76.78 (73.36 to 
80.21) 
0.79 (-2.09 to 3.67) 0.59 
  6 months 62.77 (61.51 to 
64.03) 
63.03 (61.21 to 
64.86) 
-0.64 (-3.56 to 2.29) 0.67 
  9 months 62.84 (61.39 to 
64.39) 
62.86 (60.96 to 
64.75) 
0.03 (-2.99 to 3.04) 0.98 
  12 months 62.64 (60.99 to 
64.30) 
62.43 (60.57 to 
64.30) 
-0.06 (-3.12 to 3.01) 0.97 
COMBINATION 
TRIAL 
Mean Intervention 
group (95%CI) 
N=103 
Mean Control 
group (95%CI) 
N=99 
Mean difference 
(95%CI) 
P-
value 
EQ5D Utilities***     
  Overall effect     0.04 (-0.01 to 0.09) 0.12 
  Baseline 0.48 (0.43 to 0.54) 0.52 (0.45 to 0.58)     
  3 weeks 0.64 (0.57 to 0.70) 0.60 (0.53 to 0.67) 0.06 (-0.02 to 0.14) 0.15 
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  6 weeks 0.70 (0.66 to 0.75) 0.57 (0.51 to 0.64) 0.14 (0.07 to 0.22) 0 
  3 months 0.69 (0.64 to 0.74) 0.63 (0.57 to 0.69) 0.09 (0.01 to 0.16) 0.02 
  6 months 0.69 (0.64 to 0.72) 0.69 (0.63 to 0.74) 0.01 (-0.06 to 0.09) 0.74 
  9 months 0.65 (0.59 to 0.72) 0.70 (0.64 to 0.76) -0.02 (-0.06 to 0.09) 0.62 
  12months 0.64 (0.58 to 0.70) 0.74 (0.69 to 0.80) -0.07 (-0.15 to 0.01) 0.08 
Patient satisfaction**         
  Overall effect     -0.17 (-0.56 to 0.22) 0.39 
  3 months 2.98 (2.73 to 3.22) 3.48 (3.17 to 3.78) -0.52 (-0.97 to -0.07) 0.02 
  6 months 3.05 (2.73 to 3.36) 3.13 (2.84 to 3.43) -0.056 (-0.51 to 
0.40) 
0.81 
  9 months 3.16 (2.84 to 3.47) 3.29 (2.94 to 3.63) -0.13 (-0.59 to 0.34) 0.60 
  12 months 3.32 (2.96 to 3.68) 3.08 (2.73 to 3.43) 0.10 (-0.37 to 0.58) 0.67 
MPI Pain severity**         
  Overall effect     0.02 (-0.34 to 0.38) 0.91 
  Baseline 4.00 (3.82 to 4.18) 3.96 (3.74 to 4.19)     
  3 months 2.99 (2.70 to 3.28) 3.42 (3.10 to 3.74) -0.50 (-0.94 to -0.05) 0.02 
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  6 months 3.06 (2.72 to 3.40) 2.90 (2.58 to 3.23) 0.26 (-0.18 to 0.71) 0.24 
  9 months 3.09 (2.75 to 3.43) 3.05 (2.68 to 3.42) 0.10 (-0.35 to 0.55) 0.67 
  12 months 3.07 (2.73 to 3.41) 2.61 (2.22 to 2.99) 0.68 (0.22 to 1.15) 0 
MPI interference**         
  Overall effect     0.09 (-0.24 to 0.43) 0.58 
  Baseline 3.35 (3.09 to 3.61) 3.25 (2.97 to 3.53)     
  3 months 2.84 (2.56 to 3.13) 2.92 (2.57 to 3.26) -0.18 (-0.58 to 0.21) 0.36 
  6 months 2.80 (2.46 to 3.15) 2.57 (2.27 to 2.88) 0.30 (-0.10 to 0.70) 0.14 
  9 months 2.78 (2.45 to 3.11) 2.77 (2.39 to 3.16) 0.01 (-0.40 to 0.43) 0.95 
  12 months 2.87 (2.52 to 3.23) 2.45 (2.06 to 2.82) 0.31 (-0.11 to 0.73) 0.15 
MPI Life control**         
  Overall effect     0.09 (-0.17 to 0.34) 0.49 
  Baseline 3.98 (3.76 to 4.21) 4.09 (3.91 to 4.27)     
  3 months 4.15 (3.90 to 4.39) 3.97 (3.75 to 4.19) 0.28 (-0.05 to 0.61) 0.09 
  6 months 4.16 (3.92 to 4.41) 4.10 (3.86 to 4.34) 0.10 (-0.23 to 0.44) 0.54 
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  9 months 4.06 (3.77 to 4.36) 4.09 (3.81 to 4.38) -0.02 (-0.36 to 0.32) 0.91 
  12 months 4.07 (3.78 to 4.35) 4.25 (3.96 to 4.54) -0.05 (-0.40 to 0.30) 0.77 
MPI Affective 
distress** 
        
  Overall effect     0.03 (-0.15 to 0.21) 0.74 
  Baseline 2.66 (2.49 to 2.83) 2.62 (2.47 to 2.78)     
  3 months 2.53 (2.36 to 2.70) 2.68 (2.48 to 2.88) -0.20 (-0.43 to 0.04) 0.10 
  6 months 2.58 (2.40 to 2.76) 2.48 (2.30 to 2.66) 0.11 (-0.13 to 0.35) 0.36 
  9 months 2.67 (2.49 to 2.85) 2.61 (2.43 to 2.80) 0.09 (-0.16 to 0.33) 0.49 
  12 months 2.57 (2.38 to 2.76) 2.43 (2.24 to 2.62) 0.17 (-0.08 to 0.42) 0.19 
MPI Support**         
  Overall effect     0.13 (-0.15 to 0.40) 0.36 
  Baseline 4.56 (4.26 to 4.86) 4.67 (4.44 to 4.90)     
  3 months 4.48 (4.16 to 4.81) 4.54 (4.25 to 4.83) 0.05 (-0.30 to 0.41) 0.76 
  6 months 4.36 (4.00 to 4.72) 4.35 (4.03 to 4.67) 0.17 (-0.18 to 0.53) 0.34 
  9 months 4.47 (4.10 to 4.83) 4.40 (4.08 to 4.72) 0.16 (-0.20 to 0.53) 0.38 
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  12 months 4.56 (4.20 to 4.92) 4.51 (4.18 to 4.85) 0.11 (-0.27 to 0.49) 0.57 
RAND-36 Physical 
health*** 
        
  Overall effect     -2.44 (-7.20 to 2.33) 0.32 
  Baseline 45.61 (41.93 to 
49.29) 
48.35 (44.39 to 
52.31) 
    
  3 months 54.66 (50.49 to 
58.82) 
50.06 (45.39 to 
54.73) 
4.20 (-1.49 to 9.89) 0.15 
  6 months 52.87 (48.00 to 
57.72) 
57.73 (53.20 to 
62.27) 
-5.39 (-11.18 to 
0.39) 
0.07 
  9 months 52.87 (48.02 to 
57.71) 
54.69 (49.40 to 
59.99) 
-2.20 (-8.11 to 3.70) 0.46 
  12 months 52.73 (47.62 to 
55.00) 
62.25 (57.51 to 
66.98) 
-8.72 (-14.77 to -
2.67) 
0.00 
RAND-36 mental 
health*** 
        
  Overall effect     -0.23 (-4.16 to 3.56) 0.88 
  Baseline 72.49 (69.34 to 
75.64) 
77.55 (74.97 to 
80.13) 
    
  3 months 74.02 (70.40 to 
77.65) 
74.84 (71.18 to 
78.49) 
1.57 (-3.02 to 6.17) 0.5 
  6 months 73.04 (69.41 to 
76.66) 
76.32 (72.63 to 
80.00) 
-0.82 (-5.48 to 3.84) 0.73 
  9 months 74.00 (70.10 to 
77.90) 
76.18 (72.74 to 
79.62) 
-0.46 (-5.20 to 4.28) 0.85 
  12 months 72.96 (68.54 to 
77.37) 
76.53 (72.66 to 
80.40) 
-1.94 (-6.79 to 2.91) 0.43 
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Values presented are model estimates of linear mixed-effects models with a random 
intercept, and adjusted for outcome at baseline and age, gender, BMI, education, 
smoking, marital status, back pain complaint history, patient expectations and baseline 
values. Regression coefficients can be interpreted as mean differences between 
interventions at a certain follow-up moment compared to baseline. Abbreviation: EQ5D; 
Utility scores based on the EuroQol5D; MPI, Multidimensional Pain Inventory; RAND-
36, Research and Development 36 item health survey. ** Higher score indicates less 
satisfaction or severe symptoms on the MPI. Range for patient satisfaction, 1-7, for MPI 
0-6. *** Higher score indicates more quality of life. Range for EQ5D utility: 0-1; for 
RAND36: 0-100. 
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eTable 3. As Treated Analysis for Pain Intensity, Functional Status, and Global Perceived Recovery, Without Protocol 
Violators Based on Intention-to-Treat Analyses 
FACET JOINT 
TRIAL (without 12 
protocol violators) 
Mean Intervention 
group (95%CI) 
N=125 
Mean Control 
group (95%CI) 
N=114 
Mean difference 
(95%CI) 
P-value     
NRS Pain*       
  2YHUDOOHIIHFW     -0.21 0.31     
(-0.62 to 0.20) 
  Baseline 7.14 7.22 - -     
(6.88 to 7.39) (6.96 to 7.47) 
  3 weeks 5.17 5.99 -0.53 0.09     
(4.73 to 5.61) (5.64 to 6.34) (-1.13 to 0.08) 
  6 weeks 5.19 5.95 -0.5 0.09     
(4.76 to 5.61) (5.61 to 6.29) (-1.08 to 0.08) 
  3 months 5.01 5.5 -0.29 0.32     
(4.59 to 5.43) (5.09 to 5.91) (-0.87 to 0.29) 
  6 months 4.61 4.92 -0.12 0.68     
(4.18 to 5.04) (4.45 to 5.38) (-0.72 to 0.47) 
  9 months 4.66 4.95 -0.05 0.87     
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(4.20 to 5.00) (4.45 to 5.44) (-0.65 to 0.55) 
  12months 4.49 4.56 0.31 0.31     
(4.00 to 4.97) (4.05 to 5.07) (-0.29 to 0.92) 
Secondary 
outcomes 
      
ODI Functioning*       
  2YHUDOOHIIHFW     0.09 0.96     
(-3.76 to 3.93) 
  Baseline 35.08 34.74 - -     
(32.39 to 37.76) (32.45 to 37.02) 
  3 months 26.03 29.61 -2.29 0.29     
(23.01 to 29.06) (26.61 to 32.61) (-6.52 to 1.93) 
  6 months 25.38 27.75 -0.58 0.79     
(22.45 to 28.30) (24.57 to 30.94) (-4.84 to 3.68) 
  9 months 25.74 24.97 2.23 0.31     
(22.74 to 28.73) (21.80 to 28.14) (-2.05 to 6.52) 
  12months 24.59 25.62 1.47 0.5     
(21.39 to 27.79) (22.20 to 29.04) (-2.84 to 5.77) 
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  Success n/N (%) 
Intervention group 
Success n/N (%) 
Control group 
RR (95%CI)§ P-value Risk difference 
(95%CI) 
NNT 
GPR Success       
  3 weeks 32/108 (29.63) 3/92 (3.26) 8.71 0.0001 29.37 4 
(3.09 to 17.85) (17.02 to 35.72) 
  6 weeks 35/119 (29.41) 7/108 (6.48) 4.24 0.0004 22.93 5 
(2.00 to 7.58) (13.52 to 32.34) 
  3 months 43/119 (36.13) 23/104 (22.12) 1.56 0.09 14.01 NA 
(0.93 to 2.34) (2.27 to 25.77) 
  6 months 46/113 (40.71) 33/99 (33.33) 1.18 0.46 7.38 NA 
(0.74 to 1.69) (-5.60 to 20.35) 
  9 months 41/106 (38.68) 36/96 (37.50) 0.91 0.69 1.18 NA 
(0.55 to 0.82) (-12.23 to 14.59) 
  12months 44/103 (42.72) 36/95 (37.89) 0.99 0.96 4.83 NA 
(0.61 to 1.44) (-8.83 to 18.48) 
 SACROILIAC 
JOINT TRIAL 
(without 7 protocol 
violators) 
Mean Intervention 
group (95%CI) 
N=116 
Mean Control 
group (95%CI) 
N=105 
Treatment effect 
(95%CI) 
P-value     
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NRS Pain       
  2YHUDOOHIIHFW     -0.41 0.06     
(-0.85 to 0.02) 
  Baseline 7.17 7.05 - -     
(6.85 to 7.48) (6.76 to 7.35) 
  3 weeks 4.96 5.93 -0.92 0.01     
(4.51 to 5.40) (5.51 to 6.35) (-1.59 to -0.24) 
  6 weeks 5.22 5.7 -0.5 0.13     
(4.81 to 5.64) (5.31 to 6.09) (-1.15 to 0.14) 
  3 months 4.77 5.44 -0.73 0.03     
(4.31 to 5.24) (4.91 to 5.97) (-1.39 to -0.07) 
  6 months 4.5 4.9 -0.28 0.4     
(4.01 to 4.98) (4.37 to 5.44) (-0.94 to 0.38) 
  9 months 5.03 5.01 0.13 0.72     
(4.55 to 5.51) (4.40 to 5.63) (-0.56 to 0.81) 
  12 months 4.65 4.73 0.03 0.93     
(4.16 to 5.13) (4.16 to 5.31) (-0.66 to 0.72) 
Secondary 
outcomes 
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ODI Functioning*       
  Overall effect     -0.31 0.86     
(-3.79 to 3.17) 
  Baseline 38.07 33.79 - -     
(35.40 to 40.74) (30.82 to 36.76) 
  3 months 27.72 29.46 -4.99 0.02     
(24.50 to 30.95) (25.69 to 33.24) (-9.27 to -0.70) 
  6 months 25.91 25.8 -0.95 0.67     
(22.91 to 29.05) (22.17 to 29.44) (-5.26 to 3.36) 
  9 months 28.4 23.83 3.88 0.08     
(25.05 to 31.75) (20.23 to 27.44) (-0.53 to 8.28) 
  12 months 27.29 24.72 1.71 0.45     
(23.89 to 30.69) (20.76 to 28.69) (-2.75 to 6.46) 
  Success n/N (%) 
Intervention group 
Success n/N (%) 
Control group 
RR (95%CI)§ P-value Risk difference 
(95%CI) 
NNT 
GPR Success       
  3 weeks 28/94 (29.79) 8/82 (9.76) 3.02 0.0048 20.03 5 
(1.44 to 5.11) (8.77 to 31.29) 
  6 weeks 40/108 (37.04) 9/89 (10.11) 3.91 0.0001 26.93 4 
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(2.06 to 6.13) (15.87 to 37.98) 
  3 months 43/110 (39.09) 17/82 (20.73) 1.96 0.01 18.36 5 
(1.17 to 2.87) (4.7 to 31.01) 
  6 months 46/103 (44.66) 26/83 (31.33) 1.39 0.16 13.33 NA 
(0.87 to 1.95) (-0.51 to 27.18) 
  9 months 36/101 (35.64) 23/73 (31.51) 1.15 0.58 4.13 NA 
(0.67 to 1.75) (-10.03 to 18.31) 
  12 months 49/102 (48.04) 23/70 (32.86) 1.41 0.14 15.18 NA 
(0.88 to 1.97) (0.52 to 29.85) 
 COMBINATION 
TRIAL 
(WITHOUT 14 
PROTOCOL 
VIOLATORS) 
Mean Intervention 
group (95%CI) 
N=93 
Mean Control 
group (95%CI) 
N=95 
Mean difference 
(95%CI) 
P-value     
NRS Pain *       
  2YHUDOOHIIHFW     -0.19 0.53     
(-0.78 to 0.40) 
  Baseline 7.28 7.45 - -     
(6.98 to 7.58) (7.14 to 7.77) 
  3 weeks 5.46 6.38 -0.58 0.19     
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(4.93 to 6.00) (5.87 to 6.90) (-1.44 to 0.28) 
  6 weeks 5.37 6.03 -0.31 0.43     
(4.86 to 5.89) (5.58 to 6.47) (-1.10 to 0.47) 
  3 months 4.74 5.96 -1.04 0.01     
(4.16 to 5.31) (5.42 to 6.50) (-1.82 to -0.25) 
  6 months 4.84 4.89 0.36 0.37     
(4.27 to 5.41) (4.27 to 5.51) (-0.44 to 1.16) 
  9 months 4.99 5.26 -0.09 0.83     
(4.42 to 5.56) (4.64 to 5.88) (-0.90 to 0.72) 
  12 months 4.85 4.41 0.67 0.12     
(4.21 to 5.50) (3.73 to 5.10) (-0.17 to 1.52) 
Secondary 
outcomes 
      
ODI Functioning*       
  2YHUDOOHIIHFW     2.52 0.25     
(-1.79 to 6.83) 
  Baseline 39.22 37.21 - -     
(36.26 to 42.18) (34.22 to 40.20) 
  3 months 28.03 33.66 -4.54 0.08     
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(224.45 to 31.60) (29.74 to 37.58) (-9.69 to 0.61) 
  6 months 30.75 28.51 5.31 0.05     
(36.32 to 35.18) (24.50 to 32.51) (0.08 to 10.54) 
  9 months 31.16 28.63 4.24 0.12     
(27.05 to 35.27) (24.36 to 32.89) (-1.06 to 9.54) 
  12 months 31.38 24.7 7.18 0.01     
(27.16 to 35.60) (20.76 to 28.65) (1.71 to 12.64) 
  Success n/N (%) 
Intervention group 
Success n/N (%) 
Control group 
RR (95%CI)§ P-value Risk difference 
(95%CI) 
NNT 
  3 weeks 17/72 (23.61) 4/53 (7.55) 2.25 0.15 16.06 NA 
(0.73 to 5.56) (3.95 to 28.18) 
  6 weeks 24/84 (28.57) 7/79 (8.86) 2.4 0.05 19.71 5 
(0.98 to 4.89) (8.20 to 31.23) 
  3 months 30/80 (37.50) 13/76 (17.10) 2.07 0.04 21.4 5 
(1.02 to 3.43) (8.02 to 35.27) 
  6 months 28/77 (36.36) 27/71 (38.03) 0.78 0.42 -1.67 NA 
(0.40 to 1.34) (-17.25 to 13.92) 
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  9 months 27/76 (35.52) 21/66 (31.81) 1.08 0.81 3.71 NA 
(0.55 to 1.78) (-11.85 to 19.27) 
  12 months 24/68 (35.29) 22/58 (37.93) 0.86 0.63 -2.64 NA 
(0.42 to 1.46) (-19.25 to 14.24) 
Values presented (for mean differences and Relative Risks) are model estimates of linear mixed-effects models with a random 
intercept, and adjusted for outcome at baseline and age, gender, BMI, education, smoking, marital status, back pain complaint history, 
patient expectations. Regression coefficients can be interpreted as mean differences between interventions at a certain follow-up 
moment compared to baseline. Abbreviations: SD, Standard Deviation; NRS, Numeric Rating Scale (0-10); GPR, Global Perceived 
Recovery (1-7; 1-2 indicate success); ODI, Oswestry Disability Index (0-100); RR, Relative Risk; NNT, Numbers Needed to Treat. * 
Higher score indicates more severe symptoms. § RRs are estimated based on the method of Zhang et al.32 7KHRYHUDOOHIIHFWPHDVXUHV
provide information over the total follow-up time of 12 months, instead of the time-by-treatment effects. 
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eTable 4. Treatment Effects for Pain Intensity, Functional Status, and Global Perceived Recovery Based on an As-Treated 
After 3 Months  
FACET JOINT TRIAL  Mean Intervention 
group (95%CI) 
N=125 
Mean Control 
group (95%CI) 
N=77 
Mean difference 
(95%CI) 
P-value     
NRS Pain*       
  Overall HIIHFW     0.1 (-0.39 to 0.58) 0.7     
  Baseline 7.14 7.07 - -     
(6.88 to 7.39)  (6.76 to 7.38) 
  3 weeks 5.17 5.6 -0.13 1.28     
(4.73 to 5.61)  (5.12 to 6.08) (-0.83 to 0.57) 
  6 weeks 5.19 5.6 -0.14 1.32     
(4.76 to 5.61)  (5.08 to 6.11)  (-0.8 to 0.52) 
  3 months 5.01 5.23 -0.02 1.05     
 (4.59 to 5.43) (4.68 to 5.77) (-0.68 to 0.64) 
  6 months 4.61 4.62 0.16 0.64     
 (4.18 to 5.04) (4.04 to 5.20) (-0.52 to 0.84) 
  9 months 4.66 4.52 0.28 0.42     
 (4.20 to 5.00)  (3.88 to 5.15) (-0.41 to 0.97) 
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  12 months 4.49 4.28 0.55 0.12     
 (4.00 to 4.97) (3.68 to 4.88)  (-0.15 to 1.2) 
Secondary outcomes       
ODI Functioning*       
  2YHUDOOHIIHFW     0.89 (-2.79 to 4.58) 0.64     
  Baseline 35.08 33.89 - -     
(32.39 to 37.76) (30.75 to 37.03) 
  3 months 26.03 27.77 -0.86 2     
(23.01 to 29.06) (23.75 to 31.79) (-1.27 to -0.45) 
  6 months 25.38 26.45 0.3 0.89     
(22.45 to 28.30) (22.28 to 30.63) (-3.87 to 4.47) 
  9 months 25.74 23.84 2.21 0.3     
(22.74 to 28.73) (19.51 to 28.16) (-2.00 to 6.42) 
  12 months 24.59 23.77 2.42 0.26     
(21.39 to 27.79) (19.60 to 27.94) (-1.81 to 6.65) 
  Success n/N (%) 
Intervention group 
Success n/N (%) 
Control group 
RR (95%CI) § P-value Risk difference 
(95%CI) 
NNT 
GPR success       
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  3 weeks 32/108 (29.63) 5/58 (8.62) 3.07 0.02 21.01 5 
(1.26 to 5.99) (9.77 to 32.25) 
  6 weeks 35/119 (29.41) 8/72 (11.11) 2.28 0.03 18.3 6 
(1.07 to 4.16)  (7.36 to 29.24)  
  3 months 43/119 (36.13) 22/71 (30.98) 1.02 0.94 5.15 NA 
(0.57 to 1.60) (-8.64 to 18.94)  
  6 months 46/113 (40.71) 26/66 (39.39) 0.9 0.68 1.32 NA 
(0.52 to 1.38)  (-13.55 to 
16.18)  
  9 months 41/106 (38.67) 27/62 (43.55) 0.75 0.25 -4.88 NA 
(0.42 to 1.18) (-20.31 to 
10.57)  
  12 months 44/103 (42.72) 28/61 (45.90) 0.75 0.25 -3.18 NA 
(0.42 to 1.19) (-18.92 to 
12.55)  
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eTable 4. Treatment Effects for Pain Intensity, Functional Status, and Global Perceived Recovery Based on an As-Treated 
After 3 Months (continued) 
SACROILIAC JOINT 
TRIAL  
Mean Intervention 
group (95%CI) 
N=125 
Mean Control 
group (95%CI) 
N=77 
Mean difference 
(95%CI) 
P-value   
NRS Pain*       
  Overall effect    - 
-WR 
0.44   
  Baseline  
WR 
 
WR 
- -   
  3 weeks 4.96  
(4.51 to 5.40) 
 
WR 
- 
-WR 
0.14   
  6 weeks 5.22  
(4.81 to 5.64) 
 
WR 
- 
-WR 
0.58   
  3 months 4.77  
(4.31 to 5.24) 
 
WR 
- 
-WR 
0.86   
  6 months 4.50   
(4.01 to 4.98) 
 
WR 
- 
-WR 
0.79   
  9 months 5.03   
(4.55 to 5.51) 
 
WR 
- 
-WR 
0.67   
  12 months 4.65   
(4.16 to 5.13) 
 
WR 
 
-WR 
0.71   
Secondary outcomes       
ODI Functioning*       
  Overall effect    2.26  
(-1.83 to 6.35) 
0.28   
  Baseline 38.07  
(35.40 to 40.74) 
31.81  
(28.21 to 35.34) 
- -   
  3 months 27.72  24.60  0.03  0.99   
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(24.50 to 30.95) (20.19 to 29.01) (-4.95 to 5.00) 
  6 months 25.91  
(22.91 to 29.05) 
23.24  
(18.78 to 27.70) 
1.12  
(-3.86 to 6.10) 
0.66   
  9 months 28.40  
(25.05 to 31.75) 
22.10  
(17.09 to 27.09) 
4.82  
(-0.30 to 9.94) 
0.06   
  12 months 27.29  
(23.89 to 30.69) 
21.07  
(16.57 to 25.58) 
3.64  
(-1.52 to 8.81) 
0.17   
 Success n/N (%) 
Intervention group 
Success n/N (%) 
Control group 
RR (95%CI) § P-value Risk difference 
(95%CI) 
NNT 
GPR Success       
  3 weeks 28/94 (29.78) 6/57 (10.53) 2.70 
(1.61 to 5.06) 
0.024 19.25  
(7.06 to 31.47) 
5 
  6 weeks 40/108 (37.04) 6/60 (10.00) 3.58 
(1.67 to 6.09) 
0.002 27.04 
(15.18 to 38.89) 
4 
  3 months 43/110 (39.09) 15/52 (28.85) 1.40 
(0.78 to 2.12) 
0.23 10.24  
(-5.08 to 25.57) 
NA 
  6 months 46/103 (44.66) 17/52 (32.69) 1.34 
(0.78 to 1.96) 
0.26 11.97 
(-3.99 to 27.93) 
NA 
  9 months 36/101 (35.64) 13/45 (28.88) 1.32 
(0.69 to 2.09) 
0.37 6.76  
(-9.45 to 22.96) 
NA 
  12 months 49/102 (48.03) 14/43 (32.56) 1.44 
(0.82 to 2.09) 
0.18 15.47  
(-1.55 to 32.52) 
NA 
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eTable 4. Treatment Effects for Pain Intensity, Functional Status, and Global Perceived Recovery Based on an As-Treated 
After 3 Months (continued) 
COMBINATION 
TRIAL  
Mean 
Intervention 
group (95%CI) 
N=103 
Mean Control 
group (95%CI) 
N=68 
Mean difference 
(95%CI) 
P-value   
NRS Pain (SD)*       
  Overall effect    -0.22  
(-0.85 to 0.40) 
0.48   
  Baseline 7.19  
(6.91 to 7.48) 
7.47  
(7.08 to 7.87) 
- -   
  3 weeks 5.45  
(4.95 to 5.95) 
6.66  
(6.11 to 7.20) 
-0.75  
(-1.70 to 0.19) 
0.12   
  6 weeks 5.37  
(4.89 to 5.85) 
5.96  
(5.37 to 6.56) 
-0.08  
(-0.91 to 0.75) 
0.85   
  3 months 4.77  
(4.25 to 5.00) 
5.64  
(4.94 to 6.34) 
-0.73  
(-1.56 to 0.11) 
0.09   
  6 months 4.92  
(4.39 to 5.44) 
5.36  
(4.57 to 6.14) 
-0.07  
(-0.93 to 0.78) 
0.87   
  9 months 5.01  
(4.47 to 5.56) 
5.38  
(4.60 to 6.15) 
-0.26  
(-1.14 to 0.61) 
0.55   
  12 months 4.85  
(4.24 to 5.46) 
4.53  
(3.60 to 5.46) 
0.56  
(-0.34 to 1.45) 
0.23   
Secondary outcomes       
ODI Functioning*       
  Overall effect    1.59  
(-2.97 to 6.15) 
0.49   
  Baseline 39.06  
(36.25 to 41.87) 
36.34  
(32.79 o 38.90) 
- -   
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Values presented (for mean differences and Relative Risks) are model estimates of linear mixed-effects models with a random 
intercept, and adjusted for outcome at baseline and age, gender, BMI, education, smoking, marital status, back pain complaint history, 
patient expectations. Regression coefficients can be interpreted as mean differences between interventions at a certain follow-up 
moment compared to baseline. Abbreviations: SD, Standard Deviation; NRS, Numeric Rating Scale (0-10); GPR, Global Perceived 
Recovery (1-7, 1-2 indicate success); ODI, Oswestry Disability Index (0-100); RR, Relative Risk; NNT, Numbers Needed to Treat. * 
  3 months 28.00  
(24.65 to 31.35) 
30.96  
(26.08 to 35.84) 
-3.10  
(-8.55 to 2.34) 
1.74   
  6 months 30.24  
(26.14 to 34.34) 
30.09  
(24.51 to 35.67) 
2.31  
(-3.25 to 7.88) 
0.42   
  9 months 30.73  
(26.83 to 34.63) 
27.74  
(22.00 to 33.48) 
2.89  
(-2.83 to 8.60) 
0.32   
  12 months 31.20  
(27.20 to 35.20) 
23.94  
(18.51 to 29.38) 
6.03  
(0.78 to 11.89) 
0.04   
 Success n/N (%) 
Intervention 
group 
Success n/N (%) 
Control 
group 
RR (95%CI) § P-value Risk difference  
(95%CI) 
NNT 
GPR success       
  3 weeks 17/77 (22.07) 2/33 (6.06) 3.03 
(0.69 to 8.80) 
0.13 16.01  
(3.68 to 28.35) 
NA 
  6 weeks 25/90 (27.78) 5/52 (9.62) 2.16 
(0.76 to 4.89) 
0.14 18.16 
(5.92 to 30.40) 
NA 
  3 months 30/88 (34.09) 10/50 (20.00) 1.77 
(1.64 to 1.90) 
<0.000
1 
14.09  
(-0.78 to 28.96) 
7 
  6 months 30/85 (35.29) 15/45 (33.33) 0.92 
(0.40 to 1.68) 
0.81 1.96  
(-15.15 to 19.08) 
NA 
  9 months 29/82 (35.36) 13/41 (31.71) 1.13 
(0.49 to 1.98) 
0.74 3.65  
(-13.95 to 21.26) 
NA 
  12 months 26/75 (34.67) 11/36 (30.56) 1.19 
(0.38 to 3.72) 
0.76 4.11  
(-14.39 to 22.62) 
NA 
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Higher score indicates more severe symptoms. § RRs are estimated based on the method of Zhang et al.32 7KHRYHUDOOHIIHFWPHDVXUHV
provide information over the total follow-up time of 12 months, instead of the time-by-treatment effects. 
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eTable 5. Treatment Effects for Complete Cases for Pain Intensity, Functional Status, and Global Perceived Recovery Based 
on Intention-To-Treat Analyses 
FACET JOINT 
TRIAL 
Mean Intervention 
group (95%CI) 
N=72 
Mean Control 
group (95%CI) 
N=80 
Mean difference 
(95%CI) 
P-
value 
   
NRS Pain*       
  Overall HIIHFW   -0.44 (-0.96 to 0.07) 0.09    
  Baseline 6.94 7.14 - -    
(6.59 to 7.30) (6.85 to 7.42) 
  3 weeks 5.15 5.86 -0.54 0.14    
(4.63 to 5.68) (5.46 to 6.26) (-1.25 to 0.18) 
  6 weeks 4.94 5.89 -0.77 0.03    
(4.42 to 5.47) (5.45 to 6.32) (-1.48 to -0.06) 
  3 months 4.47 5.21 -0.57 0.12    
(3.97 to 4.97) (4.71 to 5.72) (-1.28 to 0.15) 
  6 months 4.32 4.81 -0.32 0.38    
(3.79 to 4.85) (4.27 to 5.35) (-1.03 to 0.39) 
  9 months 4.17 4.84 -0.5 0.17    
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(3.62 to 4.71) (4.28 to 5.39) (-1.21 to 0.21) 
  12 months 4.18 4.31 0.04 0.91    
(3.59 to 4.77) (3.75 to 4.88) (-0.67 to 0.75) 
Secondary outcomes       
ODI Functioning*       
  Overall HIIHFW   -1.17 (-4.89 to 2.55) 0.54    
  Baseline 34.28 33.47 - -    
(31.02 to 37.53) (30.99 to 35.96) 
  3 months 23.31 26.9 -3.6 0.1    
(19.80 to 26.81) (23.75 to 30.05) (-7.83 to 0.63) 
  6 months 24.06 25.1 -1.05 0.63    
(20.48 to 27.63) (21.75 to 28.45) (-5.28 to 3.18) 
  9 months 23.58 24.25 -0.67 0.76    
(20.23 to 26.94) (21.05 to 27.45) (-4.90 to 2.56) 
  12 months 24.22 23.57 0.64 0.77    
(20.46 to 27.99) (20.22 to 26.93) (-3.59 to 4.87) 
 Success n/N (%) 
Intervention 
group 
Success n/N (%) 
Control group 
RR (95%CI) § P-
value 
Risk difference 
(95%CI) 
NNT 
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GPR Success       
  3 weeks 22/72 (30.56) 5/80 (6.25) 4.83 0.0011 24.31 4 
(1.98 to 9.10) (12.42 to 36.19) 
  6 weeks 20/72 (27.78) 8/80 (10.00) 2.73 0.13 17.88 NA 
(0.72 to 6.45) (5.52 to 30.04) 
  3 months 31/72 (43.06) 21/80 (26.25) 1.63 0.07 16.81 NA 
(0.95 to 1.88) (1.85 to 31.76) 
  6 months 31/72 (43.06) 30/80 (37.50) 1.14 0.61 5.56 NA 
(0.67 to 1.65) (-10.04 to 21.16) 
  9 months 30/72 (41.67) 30/80 (37.50) 1.09 0.72 4.17 NA 
(0.63 to 1.61) (-11.40 to 19.73) 
  12 months 31/72 (43.06) 33/80 (41.25) 1.02 0.92 1.81 NA 
(0.84 to 1.49) (-13.92 to 17.53) 
SACROILIAC JOINT 
TRIAL 
Mean Intervention 
group (95%CI) 
N=75 
Mean Control 
group (95%CI) 
N=57 
Mean difference 
(95%CI) 
P-
value 
   
NRS Pain*       
  Overall HIIHFW   -0.29 (-0.84 to 0.25) 0.29    
  Baseline 7.07 7.12 - -    
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(6.66 to 7.47) (6.68 to 7.57) 
3 weeks 5 6.14 -1 0.01    
(4.49 to 5.51) (5.61 to 6.67) (-1.80 to -0.20) 
6 weeks 5.09 5.95 -0.74 0.07    
(4.60 to 5.59) (5.43 to 6.46) (-1.54 to 0.06) 
3 months 4.63 5.43 -0.7 0.09    
(4.02 to 5.23) (4.75 to 6.11) (-1.50 to 0.10) 
6 months 4.44 4.37 0.18 0.66    
(3.86 to 5.02) (3.70 to 5.04) (-0.62 to 0.98) 
9 months 5.05 4.75 0.42 0.31    
(4.51 to 5.59) (4.05 to 5.46) (-0.38 to 1.22) 
12 months 4.65 4.7 0.06 0.88    
(4.09 to 5.22) (4.05 to 5.36) (-0.74 to 0.86) 
Secondary outcomes       
ODI Functioning*       
Overall HIIHFW   -0.31 (3.47 to 2.85) 0.53    
Baseline 37.95 34.46 - -    
(34.55 to 41.34) (30.68 to 38.23) 
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3 months 27.12 30.46 -5.17 0.07    
(22.91 to 31.33) (25.54 to 35.38) (-9.28 to -1.06) 
6 months 26.03 22.95 0.45 0.47    
(22.26 to 29.80) (18.91 to 26.98) (-3.87 to 4.36) 
9 months 29.2 22.6 2.84 0.03    
(25.19 to 33.21) (18.66 to 26.53) (-1.27 to 6.95) 
12 months 27.79 23.82 0.84 0.3    
(23.71 to 31.86) (19.56 to 28.09) (-3.28 to 4.95) 
 Success n/N (%) 
Intervention 
group 
Success n/N (%) 
Control group 
RR (95%CI) § P-
value 
Risk difference 
(95%CI) 
NNT 
GPR Success       
3 weeks 21/75 (28.00) 7/57 (12.28) 2.32 0.049 15.72 6 
(1.00 to 4.33) (2.46 to 28.98) 
6 weeks 29/75 (38.66) 5/57 (8.78) 4.53 0.001 29.88 3 
(2.00 to 7.64) (16.65 to 43.14) 
3 months 31/75 (41.33) 14/57 (24.56) 1.7 0.08 16.77 NA 
(0.93 to 2.58) (0.99 to 32.55) 
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6 months 35/75 (46.66) 23/57 (40.35) 1.15 0.55 6.31 NA 
(0.68 to 1.65) (-10.70 to 23.34) 
9 months 27/75 (36.00) 20/57 (35.08) 1.03 0.94 0.92 NA 
(0.55 to 1.62) (-15.57 to 17.39) 
12 months 36/75 (48.00) 21/57 (36.84) 1.31 0.28 11.16 NA 
(0.78 to 1.85) (-5.71 to 28.03) 
COMBINATION 
TRIAL 
Mean Intervention 
group (95%CI) 
N=60 
Mean Control 
group (95%CI) 
N=45 
Mean difference 
(95%CI) 
P-
value 
   
NRS Pain (SD)*       
2YHUDOOHIIHFW   0.17 (-0.52 to 0.85) 0.63    
Baseline 7.3 7.47 - -    
(6.97 to 7.63) (7.09 to 7.84) 
3 weeks 5.4 6.39 -0.85 0.1    
(4.78 to 6.00) (5.63 to 7.04) (-1.87 to 0.17) 
6 weeks 5.73 5.93 0.03 0.95    
(5.19 to 6.27) (5.24 to 6.53) (-0.89 to 0.95) 
3 months 5.1 5.67 -0.6 0.2    
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(4.49 to 5.71) (5.04 to 6.47) (-1.52 to 0.31) 
6 months 4.98 4.37 0.81 0.08    
(4.37 to 5.60) (3.56 to 5.06) (-0.10 to 1.73) 
9 months 5.17 5.02 0.31 0.5    
(4.55 to 5.79) (4.23 to 5.73) (-0.60 to 1.23) 
12 months 4.88 4.22 0.8 0.09    
(4.18 to 5.58) (3.47 to 4.98) (-0.12 to 1.72) 
Secondary outcomes       
ODI Functioning (SD)*       
Overall HIIHFW   4.23 (-0.34 to 8.80) 0.07    
Baseline 38 37.16 - -    
(34.61 to 41.39) (32.48 to 41.83) 
3 months 29.63 33.11 -2.85 0.32    
(25.68 to 33.58) (28.33 to 37.89) (-8.46 to 2.76) 
6 months 30.6 24.96 6.86 0.02    
(26.06 to 35.14) (20.29 to 28.77) (1.25 to 12.47) 
9 months 31.03 26.22 6.36 0.03    
(26.55 to 35.51) (21.71 to 30.74) (0.75 to 11.97) 
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12 months 30.27 25.3 6.56 0.02    
(25.79 to 34.74) (20.89 to 28.98) (0.95 to 12.17) 
 Success n/N (%) 
Intervention 
group 
Success n/N (%) 
Control group 
RR (95%CI) § P-
value 
Risk difference 
(95%CI) 
NNT 
GPR Success       
3 weeks 10/60 (16.67) 2/45 (4.44) 2.57 0.23 12.23 NA 
(0.53 to 9.17) (1.03 to 23.41) 
6 weeks 14/60 (23.33) 5/45 (11.11) 1.68 0.36 12.22 NA 
(0.53 to 4.10) (-1.88 to 26.32) 
3 months 17/60 (28.33) 8/45 (17.78) 1.61 0.32 10.55 NA 
(0.61 to 3.24) (-5.41 to 26.52) 
6 months 20/60 (33.33) 22/45 (47.89) 0.58 0.11 -14.56 NA 
(0.24 to 1.10) (-34.41 to 3.30) 
9 months 19/60 (31.67) 16/45 (35.56) 0.78 0.5 -3.89 NA 
(0.32 to 1.49) (-22.17 to 14.39) 
12 months 19/60 (31.67) 16/45 (35.56) 0.48 0.5 -3.89 NA 
(0.32 to 1.49) (-22.17 to 14.39) 
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Values presented (for mean differences and Relative Risks) are model estimates of linear mixed-effects models with a random 
intercept, and adjusted for outcome at baseline and age, gender, BMI, education, smoking, marital status, back pain complaint history, 
patient expectations. Regression coefficients can be interpreted as mean differences between interventions at a certain follow-up 
moment compared to baseline. Abbreviations: SD, Standard Deviation; NRS, Numeric Rating Scale (0-10); GPR, Global Perceived 
Recovery (1-7, 1-2 indicate success); ODI, Oswestry Disability Index (0-100); RR, Relative Risk; NNT, Numbers Needed to Treat. * 
Higher score indicates more severe symptoms. § RRs are estimated based on the method of Zhang et al.32 7KHRYHUDOOHIIHFWPHDVXUHV
provide information over the total follow-up time of 12 months, instead of the time-by-treatment effects. 
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